Member Publications

Members of the NASH Roundtable™ contribute important research to the public domain through peer-reviewed articles in medical journals. Below is a selection of recent research co-authored by Roundtable members. For a comprehensive search of NASH-related research by Roundtable members and others, visit pubmed.gov.

Filter

March, 2023

Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.

Pennisi G, Enea M, Falco V, Aithal GP, Palaniyappan N, Yilmaz Y, Boursier J, Cassinotto C, de Lédinghen V, Chan WK, Mahadeva S, Eddowes P, Newsome P, Karlas T, Wiegand J, Wong VW, Schattenberg JM, Labenz C, Kim W, Lee MS, Lupsor-Platon M, Cobbold JFL, Fan JG, Shen F, Staufer K, Trauner M, Stauber R, Nakajima A, Yoneda M, Bugianesi E, Younes R, Gaia S, Zheng MH, Cammà C, Anstee QM, Mózes FE, Pavlides M, Petta S.Hepatology. 2023 Mar 17. doi: 10.1097/HEP.0000000000000351.

View Publication
March, 2023

Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment.

Llovet JM, Willoughby CE, Singal AG, Greten TF, Heikenwälder M, El-Serag HB, Finn RS, Friedman SL.Nat Rev Gastroenterol Hepatol. 2023 Mar 17. doi: 10.1038/s41575-023-00754-7.

View Publication
March, 2023

Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.

Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kjær MS, Krarup N, Lawitz E, Ratziu V, Sanyal AJ, Schattenberg JM, Newsome PN; NN9931-4492 investigators. Lancet Gastroenterol Hepatol. 2023 Mar 16:S2468-1253(23)00068-7. doi: 10.1016/S2468-1253(23)00068-7.

View Publication
March, 2023

Review article: The need for more efficient and patient-oriented drug development pathways in NASH-setting the scene for platform trials.

Pericàs JM, Di Prospero NA, Anstee QM, Mesenbrinck P, Kjaer MS, Rivera-Esteban J, Koenig F, Sena E, Pais R, Manzano R, Genescà J, Tacke F, Ratziu V; EU-PEARL NASH Investigators. Aliment Pharmacol Ther. 2023 Mar 14. doi: 10.1111/apt.17456.  

View Publication
March, 2023

Implications of comorbidities in nonalcoholic fatty liver disease.

Song SJ, Wong VW. Clin Mol Hepatol. 2023 Mar 14. doi: 10.3350/cmh.2023.0066.  

View Publication
March, 2023

Corrigendum to: “Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort<sup>☆</sup>” [J Hepatol (2020) 505-515].

Anstee QM, Darlay R, Cockell S, Meroni M, Govaere O, Tiniakos D, Burt AD, Bedossa P, Palmer J, Liu YL, Aithal GP, Allison M, Yki-Järvinen H, Vacca M, Dufour JF, Invernizzi P, Prati D, Ekstedt M, Kechagias S, Francque S, Petta S, Bugianesi E, Clement K, Ratziu V, Schattenberg JM, Valenti L, Day CP, Cordell HJ, Daly AK; EPoS Consortium Investigators. J Hepatol. 2023 Mar 13:S0168-8278(23)00160-5. doi: 10.1016/j.jhep.2023.02.028.   

View Publication
March, 2023

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.

Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, Kleiner DE, Loomba R. Hepatology. 2023 Mar 17. doi: 10.1097/HEP.0000000000000323.

View Publication
March, 2023

Prebiotics targeting gut-liver axis to treat non-alcoholic fatty liver disease.

Castelnuovo G, Perez-Diaz-Del-Campo N, Guariglia M, Poggiolini I, Armandi A, Rosso C, Caviglia GP, Bugianesi E. Minerva Gastroenterol (Torino). 2023 Mar 9. doi: 10.23736/S2724-5985.23.03361-2.

View Publication
March, 2023

Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints.

Meyer EL, Mesenbrink P, Di Prospero NA, Pericàs JM, Glimm E, Ratziu V, Sena E, König F; EU-PEARL NASH Investigators. PLoS One. 2023 Mar 9;18(3):e0281674. doi: 10.1371/journal.pone.0281674.

View Publication
March, 2023

The global burden of metabolic disease: Data from 2000 to 2019.

Chew NWS, Ng CH, Tan DJH, Kong G, Lin C, Chin YH, Lim WH, Huang DQ, Quek J, Fu CE, Xiao J, Syn N, Foo R, Khoo CM, Wang JW, Dimitriadis GK, Young DY, Siddiqui MS, Lam CSP, Wang Y, Figtree GA, Chan MY, Cummings DE, Noureddin M, Wong VW, Ma RCW, Mantzoros CS, Sanyal A, Muthiah MD. Cell Metab. 2023 Mar 7;35(3):414-428.e3. doi: 10.1016/j.cmet.2023.02.003.

View Publication
March, 2023

Validation of a Clinical Risk-Based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort.

Sanyal AJ, Munoz B, Cusi K, Barritt AS 4th, Muthiah M, Mospan AR, Reddy KR, Firpi-Morell R, Thuluvath PJ, Bhamidimarri KR, Fried MW; TARGET-NASH Investigators. Clin Gastroenterol Hepatol. 2023 Mar 3:S1542-3565(23)00167-2. doi: 10.1016/j.cgh.2023.02.024.

View Publication
March, 2023

Prevalence of non-alcoholic fatty liver disease in patients with rheumatoid arthritis: A systematic review and meta-analysis.

Zamani M, Alizadeh-Tabari S, Chitkara P, Singh S, Loomba R. Clin Gastroenterol Hepatol. 2023 Mar 3:S1542-3565(23)00164-7. doi: 10.1016/j.cgh.2023.02.021.

View Publication
March, 2023

Using Real-World Electronic Health Record Data to Assess Chronic Disease Screening in Children: A Case Study of Non-Alcoholic Fatty Liver Disease.

Kraus EM, Pierce SL, Porter R, Kompaniyets L, Vos MB, Blanck HM, King RJ, Goodman AB. Child Obes. 2023 Mar 1. doi: 10.1089/chi.2022.0208.

View Publication
March, 2023

Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis.

Loomba R, Huang DQ, Sanyal AJ, Anstee QM, Trauner M, Lawitz EJ, Ding D, Ma L, Jia C, Billin A, Huss RS, Chung C, Goodman Z, Wong VW, Okanoue T, Romero-Gómez M, Abdelmalek MF, Muir A, Afdhal N, Bosch J, Harrison S, Younossi ZM, Myers RP. Gut. 2023 Mar;72(3):581-589. doi: 10.1136/gutjnl-2022-327777.

View Publication
February, 2023

Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients.

Siddiqui MS, Parmar D, Shaikh F, Forsgren M, Patel S, Bui AT, Boyett S, Patel V, Sanyal AJ.Liver Transpl. 2023 Feb 28. doi: 10.1097/LVT.0000000000000110.

View Publication
February, 2023

Lower Hepatic Fat Is Associated With Improved Insulin Secretion in a High-Risk Prediabetes Subphenotype During Lifestyle Intervention.

Wagner R, Heni M, Kantartzis K, Sandforth A, Machann J, Schick F, Peter A, Fritsche L, Szendrödi J, Pfeiffer AFH, Schürmann A, Blüher M, Hauner H, Seissler J, Bornstein S, Roden M, Stefan N, Birkenfeld AL, White MF, Häring HU, Fritsche A. Diabetes. 2023 Mar 1;72(3):362-366. doi: 10.2337/db22-0441.

View Publication
February, 2023

Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).

Harrison SA, Thang C, Bolze S, Dewitt S, Hallakou-Bozec S, Dubourg J, Bedossa P, Cusi K, Ratziu V, Grouin JM, Moller DE, Fouqueray P. J Hepatol. 2023 Feb 18:S0168-8278(23)00091-0. doi: 10.1016/j.jhep.2023.02.004.

View Publication
February, 2023

Trends in risk factor control and treatment among patients with non-alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory-wide study.

Zhang X, Yip TC, Tse YK, Hui VW, Li G, Lin H, Liang LY, Lai JC, Lai MS, Cheung JTK, Chan HL, Chan SL, Kong AP, Wong GL, Wong VW. Aliment Pharmacol Ther. 2023 Feb 23. doi: 10.1111/apt.17428.

View Publication
February, 2023

Lifestyle Intervention in NAFLD: Long-Term Diabetes Incidence in Subjects Treated by Web- and Group-Based Programs.

Petroni ML, Brodosi L, Armandi A, Marchignoli F, Bugianesi E, Marchesini G. Nutrients. 2023 Feb 3;15(3):792. doi: 10.3390/nu15030792.

View Publication
February, 2023

Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial.

Sanyal AJ, Lopez P, Lawitz EJ, Lucas KJ, Loeffler J, Kim W, Goh GBB, Huang JF, Serra C, Andreone P, Chen YC, Hsia SH, Ratziu V, Aizenberg D, Tobita H, Sheikh AM, Vierling JM, Kim YJ, Hyogo H, Tai D, Goodman Z, Schaefer F, Carbarns IRI, Lamle S, Martic M, Naoumov NV, Brass CA. Nat Med. 2023 Feb;29(2):392-400. doi: 10.1038/s41591-022-02200-8.

View Publication
February, 2023

Recent Research and Insights on the Disease Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.

Younossi ZM. Gastroenterol Hepatol (N Y). 2023 Feb;19(2):108-110.

View Publication
February, 2023

Genomic analysis of lean individuals with NAFLD identifies monogenic disorders in a prospective cohort study.

Zheng M, Huang DQ, Konkwo C, Agrawal S, Khera AV, Loomba R, Vilarinho S, Ajmera V. JHEP Rep. 2023 Feb 2;5(4):100692. doi: 10.1016/j.jhepr.2023.100692.

View Publication
February, 2023

Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study.

Loomba R, Lawitz EJ, Frias JP, Ortiz-Lasanta G, Johansson L, Franey BB, Morrow L, Rosenstock M, Hartsfield CL, Chen CY, Tseng L, Charlton RW, Mansbach H, Margalit M. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):120-132. doi: 10.1016/S2468-1253(22)00347-8.

View Publication
February, 2023

Healthcare and socioeconomic costs of NAFLD: a global framework to navigate the uncertainties.

Allen AM, Lazarus JV, Younossi ZM. J Hepatol. 2023 Feb 3:S0168-8278(23)00079-X. doi: 10.1016/j.jhep.2023.01.026.

View Publication
February, 2023

Sarcopenia Among Patients with Nonalcoholic Fatty Liver Disease (NAFLD) is Associated with Advanced Fibrosis.

Harring M, Golabi P, Paik JM, Shah D, Racila A, Cable R, Srishord M, Younossi ZM. Clin Gastroenterol Hepatol. 2023 Feb 25:S1542-3565(23)00155-6. doi: 10.1016/j.cgh.2023.02.013.

View Publication
February, 2023

A practical use of noninvasive tests in clinical practice to identify high-risk patients with nonalcoholic steatohepatitis.

Younossi Z, Alkhouri N, Cusi K, Isaacs S, Kanwal F, Noureddin M, Loomba R, Ravendhran N, Lam B, Nader K, Racila A, Nader F, Henry L. Aliment Pharmacol Ther. 2023 Feb;57(3):304-312. doi: 10.1111/apt.17346.

View Publication
January, 2023

The Nimble Stage 1 Study Validates Diagnostic Circulating Biomarkers for Nonalcoholic Steatohepatitis.

Sanyal A, Shankar S, Yates K, Bolognese J, Daly E, Dehn C, Neuschwander-Tetri B, Kowdley K, Vuppalanchi R, Behling CA, Tonascia J, Samir A, Sirlin C, Sherlock S, Fowler K, Heymann H, Kamphaus T, Loomba R, Calle R. Res Sq. 2023 Jan 19:rs.3.rs-2492725. doi: 10.21203/rs.3.rs-2492725/v1.

View Publication
January, 2023

Secondary bile acids improve risk prediction for non-invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease.

Liu AN, Xu CF, Liu YR, Sun DQ, Jiang L, Tang LJ, Zhu PW, Chen SD, Liu WY, Wang XD, Targher G, Byrne CD, Wong VW, Fu J, Su MM, Loomba R, Zheng MH, Ni Y. Aliment Pharmacol Ther. 2023 Jan 20. doi: 10.1111/apt.17362.

View Publication
January, 2023

Cross-Sectional and Longitudinal Performance of Non-Invasive Tests of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.

Armandi A, Rosso C, Younes R, Leeming DJ, Karsdal MA, Caviglia GP, Pérez-Diaz-Del-Campo N, D'Amato D, Abdulle A, Nicolosi A, Castelnuovo G, Saracco GM, Ribaldone DG, Bugianesi E. J Clin Med. 2023 Jan 13;12(2):650. doi: 10.3390/jcm12020650.

View Publication
January, 2023

Nonalcoholic Fatty Liver Disease Is Independently Associated With Higher All-Cause and Cause-Specific Mortality.

de Avila L, Henry L, Paik JM, Ijaz N, Weinstein AA, Younossi ZM. Clin Gastroenterol Hepatol. 2023 Jan 13:S1542-3565(23)00037-X. doi: 10.1016/j.cgh.2023.01.006.

View Publication
January, 2023

Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study.

Julián MT, Ballesta S, Pera G, Pérez-Montes de Oca A, Soldevila B, Caballería L, Morillas R, Expósito C, Martínez-Escudé A, Puig-Domingo M, Franch-Nadal J, Torán P, Cusi K, Julve J, Mauricio D, Alonso N. Front Endocrinol (Lausanne). 2023 Jan 13;13:1051958. doi: 10.3389/fendo.2022.1051958.

View Publication
January, 2023

Diabetes and cirrhosis: Current concepts on diagnosis and management.

Castera L, Cusi K. Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000263.

View Publication
January, 2023

The Predictive Role of Extracellular NAPRT for the Detection of Advanced Fibrosis in Biopsy-Proven Non-Alcoholic Fatty Liver Disease.

Armandi A, Colombo G, Rosso C, Caviglia GP, Olivero A, Abate ML, Guariglia M, Perez Diaz Del Campo N, Castelnuovo G, Ribaldone DG, Saracco GM, Genazzani AA, Bugianesi E. Int J Mol Sci. 2023 Jan 7;24(2):1172. doi: 10.3390/ijms24021172.

View Publication
January, 2023

Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial.

Brown EA, Minnich A, Sanyal AJ, Loomba R, Du S, Schwarz J, Ehman RL, Karsdal M, Leeming DJ, Cizza G, Charles ED. JHEP Rep. 2023 Jan 7;5(4):100661. doi: 10.1016/j.jhepr.2022.100661.

View Publication
January, 2023

Rational combination therapy for NASH: Insights from clinical trials and error.

Armandi A, Colombo G, Rosso C, Caviglia GP, Olivero A, Abate ML, Guariglia M, Perez Diaz Del Campo N, Castelnuovo G, Ribaldone DG, Saracco GM, Genazzani AA, Bugianesi E. Int J Mol Sci. 2023 Jan 7;24(2):1172. doi: 10.3390/ijms24021172.

View Publication
December, 2022

Adverse muscle composition is a significant risk factor for all-cause mortality in NAFLD.

Linge J, Nasr P, Sanyal AJ, Dahlqvist Leinhard O, Ekstedt M. JHEP Rep. 2022 Dec 24;5(3):100663. doi: 10.1016/j.jhepr.2022.100663.

View Publication
December, 2022

Exercise Training Is Associated With Treatment Response in Liver Fat Content by Magnetic Resonance Imaging Independent of Clinically Significant Body Weight Loss in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.

Stine JG, DiJoseph K, Pattison Z, Harrington A, Chinchilli VM, Schmitz KH, Loomba R. Am J Gastroenterol. 2022 Dec 23. doi: 10.14309/ajg.0000000000002098.

View Publication
December, 2022

Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH.

Fraser DA, Harrison SA, Schuppan D. Expert Opin Investig Drugs. 2022 Dec;31(12):1269-1278. doi: 10.1080/13543784.2022.2159804.

View Publication
December, 2022

A Class Effect Network Meta-analysis of Lipid Modulation in Non-alcoholic Steatohepatitis for Dyslipidemia

Xiao J, Ng CH, Chin YH, Tan DJH, Lim WH, Lim G, Quek J, Tang ASP, Chan KE, Soong RY, Chew N, Tay B, Huang DQ, Tamaki N, Foo R, Chan MY, Noureddin M, Siddiqui MS, Sanyal AJ, Muthiah MD. J Clin Transl Hepatol. 2022 Dec 28;10(6):1042-1049. doi: 10.14218/JCTH.2022.00095.  

View Publication
December, 2022

Vigorous physical activity provides protection against all-cause deaths among adults patients with nonalcoholic fatty liver disease (NAFLD)

Henry A, Paik JM, Austin P, Eberly KE, Golabi P, Younossi I, Henry L, Gerber L, Younossi ZM. Aliment Pharmacol Ther. 2022 Nov 15. doi: 10.1111/apt.17308. 

View Publication
November, 2022

MAFLD vs. NAFLD not an emotional political process – rather Evidence-Based Medicine

Muthiah M, Sanyal AJ, Noureddin M. Ann Hepatol. 2022 Nov 29:100883. doi: 10.1016/j.aohep.2022.100883.

View Publication
November, 2022

A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes

Ajmera V, Cepin S, Tesfai K, Hofflich H, Cadman K, Lopez S, Madamba E, Bettencourt R, Richards L, Behling C, Sirlin CB, Loomba R. J Hepatol. 2022 Nov 18:S0168-8278(22)03302-5. doi: 10.1016/j.jhep.2022.11.010.  

View Publication
November, 2022

Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients with Type 2 Diabetes and NAFLD

Kalavalapalli S, Leiva EG, Lomonaco R, Chi X, Shrestha S, Dillard R, Budd J, Romero JP, Li C, Bril F, Samraj G, Pennington J, Townsend P, Orlando F, Shetty S, Mansour L, Silva-Sombra LR, Bedossa P, Malaty J, Barb D, Gurka MJ, Cusi K. J Clin Endocrinol Metab. 2022 Nov 16:dgac660. doi: 10.1210/clinem/dgac660.  

View Publication
November, 2022

Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis

Quek J, Chan KE, Wong ZY, Tan C, Tan B, Lim WH, Tan DJH, Tang ASP, Tay P, Xiao J, Yong JN, Zeng RW, Chew NWS, Nah B, Kulkarni A, Siddiqui MS, Dan YY, Wong VW, Sanyal AJ, Noureddin M, Muthiah M, Ng CH. Lancet Gastroenterol Hepatol. 2022 Nov 15:S2468-1253(22)00317-X. doi: 10.1016/S2468-1253(22)00317-X.  

View Publication
November, 2022

Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores

Sanyal AJ, Foucquier J, Younossi ZM, Harrison SA, Newsome PN, Chan WK, Yilmaz Y, De Ledinghen V, Costentin C, Zheng MH, Wong VW, Elkhashab M, Huss RS, Myers RP, Roux M, Labourdette A, Destro M, Fournier-Poizat C, Miette V, Sandrin L, Boursier J.J Hepatol. 2022 Nov 11:S0168-8278(22)03293-7. doi: 10.1016/j.jhep.2022.10.034. Online ahead of print.PMID: 36375686 

View Publication
November, 2022

Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD

Amangurbanova M, Huang DQ, Loomba R.Aliment Pharmacol Ther. 2022 Nov 9. doi: 10.1111/apt.17292. Online ahead of print.PMID: 36349732

View Publication
November, 2022

Restoration of CD4+ T Cells during NAFLD without Modulation of the Hepatic Immunological Pattern Is Not Sufficient to Prevent HCC

Isbell M, Mirshahi F, Aqbi HF, Guo C, Saneshaw M, Koelsch N, Idowu MO, Austin D, Gelber C, Wang XY, Sanyal AJ, Manjili MH.Cancers (Basel). 2022 Nov 9;14(22):5502. doi: 10.3390/cancers14225502.PMID: 36428596

View Publication
November, 2022

Changes in abdominal adipose tissue depots assessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis

Shen W, Middleton MS, Cunha GM, Delgado TI, Wolfson T, Gamst A, Fowler KJ, Alazraki A, Trout AT, Ohliger MA, Shah SN, Bashir MR, Kleiner DE, Loomba R, Neuschwander-Tetri BA, Sanyal AJ, Zhou J, Sirlin CB, Lavine JE.J Hepatol. 2022 Nov 8:S0168-8278(22)03284-6. doi: 10.1016/j.jhep.2022.10.027. Online ahead of print.PMID: 36368598

View Publication
November, 2022

Meta-analysed numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes

Wolff G, Lin Y, Akbulut C, Brockmeyer M, Parco C, Hoss A, Sokolowski A, Westenfeld R, Kelm M, Roden M, Schlesinger S, Kuss O.ESC Heart Fail. 2022 Nov 7. doi: 10.1002/ehf2.14213. Online ahead of print.PMID: 36337026 

View Publication
November, 2022

Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH

Ratziu V, Harrison SA, Loustaud-Ratti V, Bureau C, Lawitz E, Abdelmalek M, Alkhouri N, Francque S, Girma H, Darteil R, Couchoux H, Wolf M, Sanyal A, Vonderscher J, Scalfaro P.J Hepatol. 2022 Nov 2:S0168-8278(22)03160-9. doi: 10.1016/j.jhep.2022.10.023. Online ahead of print.PMID: 36334688

View Publication
November, 2022

Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease

Tamaki N, Ahlholm N, Luukkonen PK, Porthan K, Sharpton SR, Ajmera V, Kono Y, Dave S, Ahmed A, Sundaram V, Wilkinson MJ, Patton H, Gupta H, Cervantes V, Hernandez C, Lopez SJ, Loomba R, Baumgartner A, Richards L, Arkkila PE, Nemes K, Isoniemi H, Yki-Järvinen H, Loomba R. J Clin Invest. 2022 Nov 1;132(21):e162513. doi: 10.1172/JCI162513. 

View Publication
November, 2022

MRI Quantification of Placebo Effect in Nonalcoholic Steatohepatitis Clinical Trials

Nedrud MA, Chaudhry M, Middleton MS, Moylan CA, Lerebours R, Luo S, Farjat A, Guy C, Loomba R, Abdelmalek MF, Sirlin CB, Bashir MR. Radiology. 2022 Nov 1:220743. doi: 10.1148/radiol.220743.  

View Publication
November, 2022

Dietary Recommendations for the Management of Non-alcoholic Fatty Liver Disease (NAFLD): A Nutritional Geometry Perspective

Romero-Gómez M, Aller R, Martín-Bermudo F. Semin Liver Dis. 2022 Nov;42(4):434-445. doi: 10.1055/s-0042-1757711. 

View Publication
November, 2022

Gut metagenome-derived signature predicts hepatic decompensation and mortality in NAFLD-related cirrhosis

Sharpton SR, Oh TG, Madamba E, Wang C, Yu RT, Atkins AR, Huan T, Downes M, Evans RM, Loomba R. Aliment Pharmacol Ther. 2022 Nov;56(10):1475-1485. doi: 10.1111/apt.17236.

View Publication
November, 2022

Vitality, mental health and role-physical mediate the influence of coping on depressive symptoms and self-efficacy in patients with non-alcoholic fatty liver disease: A cross-sectional study

Funuyet-Salas J, Pérez-San-Gregorio MÁ, Martín-Rodríguez A, Romero-Gómez M. J Psychosom Res. 2022 Nov;162:111045. doi: 10.1016/j.jpsychores.2022.111045.

View Publication
October, 2022

Approach to the Patient with Nonalcoholic Fatty Liver Disease

Belfort-DeAguiar R, Lomonaco R, Cusi K. J Clin Endocrinol Metab. 2022 Oct 28:dgac624. doi: 10.1210/clinem/dgac624.

View Publication
October, 2022

Non-alcoholic steatohepatitis

Romero-Gómez M. Med Clin (Barc). 2022 Oct 28;159(8):388-395. doi: 10.1016/j.medcli.2022.06.017.

View Publication
October, 2022

Accuracy of Noninvasive Diagnostic Tests for the Detection of Significant and Advanced Fibrosis Stages in Nonalcoholic Fatty Liver Disease: A Systematic Literature Review of the US Studies

Gosalia D, Ratziu V, Stanicic F, Vukicevic D, Zah V, Gunn N, Halegoua-DeMarzio D, Tran T. Diagnostics (Basel). 2022 Oct 27;12(11):2608. doi: 10.3390/diagnostics12112608.

View Publication
October, 2022

A Meta-Analysis on Associated Risk of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD)

Fu CE, Ng CH, Yong JN, Chan KE, Xiao J, Nah B, Bong SHS, Win KM, Bwa AH, Lim WH, Tan DJH, Zeng RW, Chew N, Teng ML, Siddiqui MS, Oben JA, Sanyal AJ, Wai-Sun Wong V, Noureddin M, Muthiah M. Endocr Pract. 2022 Oct 20:S1530-891X(22)00648-6. doi: 10.1016/j.eprac.2022.10.007.

View Publication
October, 2022

Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis

Jacobson IM, Wong VW, Castera L, Anstee QM, Noureddin M, Cusi K, Harrison SA, Bugianesi E, Younossi ZM. J Clin Gastroenterol. 2022 Oct 17. doi: 10.1097/MCG.0000000000001780.

View Publication
October, 2022

Prevalence of non-alcoholic fatty liver disease (NAFLD) in a cohort of patients with type 2 diabetes: the PHIGNA-DM2 study

Martínez-Ortega AJ, Piñar Gutiérrez A, Lara-Romero C, Remón Ruiz PJ, Ampuero-Herrojo J, de Lara-Rodríguez I, Romero-Gómez M, García Luna PP, Soto-Moreno A. Nutr Hosp. 2022 Oct 17;39(5):1012-1018. doi: 10.20960/nh.03969.

View Publication
October, 2022

NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity?

Chen B, Tang WHW, Rodriguez M, Corey KE, Sanyal AJ, Kamath PS, Bozkurt B, Virk HUH, Pressman GS, Lazarus JV, El-Serag HB, Krittanawong C. Semin Liver Dis. 2022 Oct 14. doi: 10.1055/s-0042-1757712.

View Publication
October, 2022

RNA binding protein HuR protects against NAFLD by suppressing long noncoding RNA H19 expression

Wang Y, Tai YL, Way G, Zeng J, Zhao D, Su L, Jiang X, Jackson KG, Wang X, Gurley EC, Liu J, Liu J, Chen W, Wang XY, Sanyal AJ, Hylemon PB, Zhou H. Cell Biosci. 2022 Oct 12;12(1):172. doi: 10.1186/s13578-022-00910-7.

View Publication
October, 2022

Impaired Myocardial Mitochondrial Respiration in Humans With Prediabetes: A Footprint of Prediabetic Cardiomyopathy

Zweck E, Scheiber D, Schultheiss HP, Kuss O, Kelm M, Roden M, Westenfeld R, Szendroedi J. Circulation. 2022 Oct 11;146(15):1189-1191. doi: 10.1161/CIRCULATIONAHA.122.058995.

View Publication
October, 2022

Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and Cons

Pericàs JM, Tacke F, Anstee QM, Di Prospero NA, Skalshøj Kjær M, Mesenbrink P, Koenig F, Genescà J, Ratziu V; EU-PEARL NASH Investigators. J Hepatol. 2022 Oct 7:S0168-8278(22)03131-2. doi: 10.1016/j.jhep.2022.09.021.

View Publication
October, 2022

The Spectrum and Impact of Metabolic Dysfunction in MAFLD. A Longitudinal Cohort Analysis of 32,683 Overweight and Obese Individuals

Chan KE, Ng CH, Fu CE, Quek J, Kong G, Goh YJ, Zeng RW, Tseng M, Aggarwal M, Nah B, Chee D, Wong ZY, Zhang S, Wang JW, Chew NW, Dan YY, Siddiqui MS, Noureddin M, Sanyal AJ, Muthiah M. Clin Gastroenterol Hepatol. 2022 Oct 3:S1542-3565(22)00926-0. doi: 10.1016/j.cgh.2022.09.028.

View Publication
October, 2022

Relative validity of a glycemic index extended food-frequency questionnaire

Goletzke J, Weber KS, Kössler T, Zaharia OP, Bódis K, Müssig K, Szendroedi J, Burkart V, Stutz B, Nöthlings U, Buyken AE, Roden M; GDS Group. Nutr Metab Cardiovasc Dis. 2022 Oct;32(10):2310-2320. doi: 10.1016/j.numecd.2022.07.007.

View Publication
October, 2022

Absolute treatment effects for the primary outcome and all-cause mortality in the cardiovascular outcome trials of new antidiabetic drugs: a meta-analysis of digitalized individual patient data

Kuss O, Akbulut C, Schlesinger S, Georgiev A, Kelm M, Roden M, Wolff G. Acta Diabetol. 2022 Oct;59(10):1349-1359. doi: 10.1007/s00592-022-01917-9. Epub 2022 Jul 25.

View Publication
September, 2022

Placebo Adverse Events in Non-Alcoholic Steatohepatitis Clinical Trials. A Pooled Analysis of 2,944 Participants

Lin Tay PW, Ng CH, Lin SY, Chin YH, Xiao J, Lim WH, Lim SY, Fu CE, Chan KE, Quek J, Hao Tan DJ, Chew N, Syn N, Keitoku T, Tamaki N, Siddiqui MS, Noureddin M, Muthiah M, Huang DQ, Loomba R. Am J Gastroenterol. 2022 Sep 30. doi: 10.14309/ajg.0000000000002042.

View Publication
September, 2022

Hyperbaric oxygen rapidly improves tissue-specific insulin sensitivity and mitochondrial capacity in humans with type 2 diabetes: a randomised placebo-controlled crossover trial

Sarabhai T, Mastrototaro L, Kahl S, Bönhof GJ, Jonuscheit M, Bobrov P, Katsuyama H, Guthoff R, Wolkersdorfer M, Herder C, Meuth SG, Dreyer S, Roden M. Diabetologia. 2022 Sep 30. doi: 10.1007/s00125-022-05797-0.

View Publication
September, 2022

Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus Non-alcoholic fatty liver disease: A longitudinal cohort analysis

Muthiah M, Ng CH, Chan KE, Fu CE, Lim WH, Tan DJH, Nah B, Kong G, Xiao J, Yong JN, Tan B, Syn N, Wang JW, Sayed N, Tan E, Chew NW, Dan YY, Siddiqui MS, Sanyal AJ, Noureddin M. Ann Hepatol. 2022 Sep 29;28(1):100762. doi: 10.1016/j.aohep.2022.100762.

View Publication
September, 2022

A poor perspective of self weight significantly increases adverse outcomes in non-alcoholic fatty liver disease (NAFLD)

Fu CE, Ng CH, Chew NWS, Heng ZEQ, Chin YH, Quek J, Lim WH, Xiao J, Chan KE, Tan DJH, Tan C, Zhang S, Koh TK, Nah B, Dan YY, Syn N, Siddiqui MS, Sanyal AJ, Noureddin M, Muthiah M. Front Med (Lausanne). 2022 Sep 28;9:977552. doi: 10.3389/fmed.2022.977552.

View Publication
September, 2022

Metabolic Factors Predict Changes in Endothelial Function During the Early Course of Type 1 and Type 2 Diabetes

Zaharia OP, Schön M, Löffler L, Strassburger K, Möser C, Yurchenko I, Bódis K, Antoniou S, Karusheva Y, Szendroedi J, Burkart V, Roden M. J Clin Endocrinol Metab. 2022 Sep 28;107(10):e4167-e4176. doi: 10.1210/clinem/dgac480.

View Publication
September, 2022

NAFLD and thyroid function: pathophysiological and therapeutic considerations

Hatziagelaki E, Paschou SA, Schön M, Psaltopoulou T, Roden M. Trends Endocrinol Metab. 2022 Sep 26:S1043-2760(22)00160-6. doi: 10.1016/j.tem.2022.08.001.

View Publication
September, 2022

The impact of fatigue on mortality of patients with non-alcoholic fatty liver disease: Data from National Health and nutrition examination survey 2005-2010 and 2017-2018

Younossi ZM, Paik JM, Golabi P, Younossi Y, Henry L, Nader F. Liver Int. 2022 Sep 26. doi: 10.1111/liv.15437.

View Publication
September, 2022

FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models

O'Farrell M, Duke G, Crowley R, Buckley D, Martins EB, Bhattacharya D, Friedman SL, Kemble G. Sci Rep. 2022 Sep 19;12(1):15661. doi: 10.1038/s41598-022-19459-z.

View Publication
September, 2022

The Cost of Diagnosing and Managing Non-alcoholic Steatohepatitis in Europe and the United States

Geier A, Heinz S, Balp MM, Brass C, Pedrosa M, Cai J, Hoad R, Sayadian AC, Rinella M, Ratziu V. J Gastrointestin Liver Dis. 2022 Sep 15;31(3):317-322. doi: 10.15403/jgld-4275.

View Publication
September, 2022

Clinical Utility of Combined MRI-PDFF and ALT Response in Predicting Histologic Response in Nonalcoholic Fatty Liver Disease

Huang DQ, Sharpton SR, Amangurbanova M, Tamaki N, Sirlin CB, Loomba R; NAFLD Research Study Group. Clin Gastroenterol Hepatol. 2022 Sep 5:S1542-3565(22)00832-1. doi: 10.1016/j.cgh.2022.08.036.

View Publication
September, 2022

Geographical similarity and differences in the burden and genetic predisposition of NAFLD

Yip TC, Vilar-Gomez E, Petta S, Yilmaz Y, Wong GL, Adams LA, de Lédinghen V, Sookoian S, Wong VW. Hepatology. 2022 Sep 5. doi: 10.1002/hep.32774.

View Publication
September, 2022

Non-alcoholic steatohepatitis

Romero-Gómez M. Med Clin (Barc). 2022 Sep 5:S0025-7753(22)00403-1. doi: 10.1016/j.medcli.2022.06.017.

View Publication
September, 2022

Interactive Role of Surrogate Liver Fibrosis Assessment and Insulin Resistance on the Incidence of Major Cardiovascular Events

Martinez-Urbistondo D, D'Avola D, Navarro-González D, Sanchez-Iñigo L, Fernandez-Montero A, Perez-Diaz-Del-Campo N, Bugianesi E, Martinez JA, Pastrana JC. J Clin Med. 2022 Sep 1;11(17):5190. doi: 10.3390/jcm11175190.

View Publication
September, 2022

Analysis of a Simulation Model to Estimate Long-term Outcomes in Patients with Nonalcoholic Fatty Liver Disease

Chhatwal J, Dalgic OO, Chen W, Samur S, Bethea ED, Xiao J, Hur C, Corey KE, Loomba R. JAMA Netw Open. 2022 Sep 1;5(9):e2230426. doi: 10.1001/jamanetworkopen.2022.30426.

View Publication
September, 2022

Diagnostic scores and scales for appraising Nonalcoholic fatty liver disease and omics perspectives for precision medicine

Perez-Diaz-Del-Campo N, Martínez-Urbistondo D, Bugianesi E, Martínez JA. Curr Opin Clin Nutr Metab Care. 2022 Sep 1;25(5):285-291. doi: 10.1097/MCO.0000000000000849. Epub 2022 Jul 5.

View Publication
September, 2022

Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world

Henry L, Paik J, Younossi ZM. Aliment Pharmacol Ther. 2022 Sep;56(6):942-956. doi: 10.1111/apt.17158. Epub 2022 Jul 26.

View Publication
August, 2022

Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH

Tan DJH, Setiawan VW, Ng CH, Lim WH, Muthiah MD, Tan EX, Dan YY, Roberts LR, Loomba R, Huang DQ. Hepatology. 2022 Aug 29. doi: 10.1002/hep.32758.

View Publication
August, 2022

Shared mechanisms between cardiovascular disease and NAFLD

Huang D, Downes M, Evans R, Witztum J, Glass C, Loomba R. Semin Liver Dis. 2022 Aug 25. doi: 10.1055/a-1930-6658.

View Publication
August, 2022

Management of NAFLD in primary care settings

Wong VWS, Zelber-Sagi S, Cusi K, Carrieri P, Wright E, Crespo J, Lazarus JV. Liver Int. 2022 Aug 20. doi: 10.1111/liv.15404

View Publication
August, 2022

Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease

Sen P, Govaere O, Sinioja T, McGlinchey A, Geng D, Ratziu V, Bugianesi E, Schattenberg JM, Vidal-Puig A, Allison M, Cockell S, Daly AK, Hyötyläinen T, Anstee QM, Orešič M. iScience. 2022 Aug 15;25(9):104949. doi: 10.1016/j.isci.2022.104949.

View Publication
August, 2022

Metabolic factors predict changes in endothelial function during the early course of type 1 and type 2 diabetes

Zaharia OP, Schön M, Löffler L, Strassburger K, Möser C, Yurchenko I, Bódis K, Antoniou S, Karusheva Y, Szendroedi J, Burkart V, Roden M. J Clin Endocrinol Metab. 2022 Aug 15:dgac480. doi: 10.1210/clinem/dgac480.

View Publication
August, 2022

Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD

Kim BK, Tamaki N, Imajo K, Yoneda M, Sutter N, Jung J, Lin T, Tu XM, Bergstrom J, Nguyen K, Nguyen L, Le T, Madamba E, Richards L, Valasek MA, Behling C, Sirlin CB, Nakajima A, Loomba R. J Hepatol. 2022 Aug 13:S0168-8278(22)02984-1. doi: 10.1016/j.jhep.2022.07.020.

View Publication
August, 2022

Historical Changes in Weight Classes and the Influence of NAFLD Prevalence: A Population Analysis of 34,486 Individuals

Nah BKY, Ng CH, Chan KE, Tan C, Aggarwal M, Zeng RW, Xiao J, Chin YH, Tan EXX, Ren YP, Chee D, Neo J, Chew NWS, Tseng M, Siddiqui MS, Sanyal AJ, Dan YY, Muthiah M. Int J Environ Res Public Health. 2022 Aug 11;19(16):9935. doi: 10.3390/ijerph19169935.

View Publication
August, 2022

Developing and pilot testing an oral health screening tool for diabetes care providers

George A, Poudel P, Kong A, Villarosa A, Calache H, Arora A, Griffiths R, Wong VW, Gussy M, Martin RE, Lau P. BMC Prim Care. 2022 Aug 11;23(1):202. doi: 10.1186/s12875-022-01798-5.

View Publication
August, 2022

Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality

Ng CH, Wong ZY, Chew NWS, Chan KE, Xiao J, Sayed N, Lim WH, Tan DJH, Loke RWK, Tay PWL, Yong JN, Kong G, Huang DQ, Wang JW, Chan M, Dalakoti M, Tamaki N, Noureddin M, Siddiqui MS, Sanyal AJ, Muthiah M. Front Cardiovasc Med. 2022 Aug 8;9:942753. doi: 10.3389/fcvm.2022.942753.

View Publication
August, 2022

Living in the non-alcoholic fatty liver disease silent epidemic: a qualitative systematic review of patients’ perspectives

Ng CH, Lim WH, Chin YH, Yong JN, Zeng RW, Chan KE, Tan DJH, Fu CE, Tang ASP, Goh LH, Devi K, Chew NWS, Mak LL, Tamaki N, Huang DQ, Noureddin M, Siddiqui MS, Loomba R, Sanyal AJ, Muthiah M. Aliment Pharmacol Ther. 2022 Aug;56(4):570-579. doi: 10.1111/apt.17121.

View Publication
July, 2022

The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database

Alkhouri N, Almomani A, Le P, Payne JY, Asaad I, Sakkal C, Vos M, Noureddin M, Kumar P. BMC Gastroenterol. 2022 Jul 30;22(1):366. doi: 10.1186/s12876-022-02430-7.

View Publication
July, 2022

Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals

Saponaro C, Sabatini S, Gaggini M, Carli F, Rosso C, Positano V, Armandi A, Caviglia GP, Faletti R, Bugianesi E, Gastaldelli A. Liver Int. 2022 Jul 28. doi: 10.1111/liv.15377.

View Publication
July, 2022

Treatments for obesity in the context of nonalcoholic steatohepatitis and mental health

Sharma A, Albhaisi S, Sanyal AJ. Clin Liver Dis (Hoboken). 2022 Jul 16;20(2):48-51. doi: 10.1002/cld.1219.

View Publication
July, 2022

Behavioral health disorders related to nonalcoholic steatohepatitis

Sharma A, Albhaisi S, Sanyal AJ. Clin Liver Dis (Hoboken). 2022 Jul 16;20(2):43-47. doi: 10.1002/cld.1211.

View Publication
July, 2022

Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients

Lawitz EJ, Li KW, Nyangau E, Field TJ, Chuang JC, Billin A, Wang L, Wang Y, Huss RS, Chung C, Subramanian GM, Myers RP, Hellerstein MK. J Lipid Res. 2022 Jul 11;63(9):100250. doi: 10.1016/j.jlr.2022.100250.

View Publication
July, 2022

Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey

Rinella M, Cryer DR, Articolo A, Fisher T, Schneider J, Nadolsky K. BMC Gastroenterol. 2022 Jul 10;22(1):335. doi: 10.1186/s12876-022-02410-x.

View Publication
July, 2022

The Prevalence and Determinants of NAFLD and MAFLD and Their Severity in the VA Primary Care Setting

Thrift AP, Nguyen TH, Pham C, Balakrishnan M, Kanwal F, Loomba R, Duong HT, Ramsey D, El-Serag HB. Clin Gastroenterol Hepatol. 2022 Jul 8:S1542-3565(22)00603-6. doi: 10.1016/j.cgh.2022.05.046.

View Publication
July, 2022

Liver stiffness accuracy by MR elastography in histologically proven non-alcoholic fatty liver disease patients: a Spanish cohort

Lara Romero C, Liang JX, Fernández Lizaranzazu I, Ampuero Herrojo J, Castell J, Del Prado Alba C, Domínguez Pascual I, Romero Gómez M. Rev Esp Enferm Dig. 2022 Jul 6. doi: 10.17235/reed.2022.8777/2022.

View Publication
July, 2022

Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease

Lin H, Yip TC, Zhang X, Li G, Tse YK, Hui VW, Liang LY, Lai JC, Chan SL, Chan HL, Wong GL, Wong VW. Hepatology. 2022 Jul 5. doi: 10.1002/hep.32633

View Publication
July, 2022

Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer

Huang DQ, Singal AG, Kono Y, Tan DJH, El-Serag HB, Loomba R. Cell Metab. 2022 Jul 5;34(7):969-977.e2. doi: 10.1016/j.cmet.2022.05.003.

View Publication
July, 2022

The scaffold-dependent function of RIPK1 in experimental non-alcoholic steatohepatitis

Pistorio V, Tokgozoglu J, Ratziu V, Gautheron J. J Mol Med (Berl). 2022 Jul;100(7):1039-1042. doi: 10.1007/s00109-022-02217-z.

View Publication
July, 2022

Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants

Ajmera V, Kim BK, Yang K, Majzoub AM, Nayfeh T, Tamaki N, Izumi N, Nakajima A, Idilman R, Gumussoy M, Oz DK, Erden A, Quach NE, Tu X, Zhang X, Noureddin M, Allen AM, Loomba R. Gastroenterology. 2022 Jul 2:S0016-5085(22)00735-1. doi: 10.1053/j.gastro.2022.06.073.

View Publication
July, 2022

Fatty liver indices and their association with glucose metabolism in pregnancy – An observational cohort study.

Linder T, Eppel D, Kotzaeridi G, Rosicky I, Yerlikaya-Schatten G, Kiss H, Weißhaupt K, Henrich W, Bozkurt L, Tura A, Roden M, Göbl CS. Diabetes Res Clin Pract. 2022 Jul;189:109942. doi: 10.1016/j.diabres.2022.109942.

View Publication
July, 2022

A Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Insulin Dimer

Walford GA, Duncan KE, Hernandez M, Vaddady P, Hompesch M, Morrow L, Stoch SA. Clin Pharmacol Ther. 2022 Jul;112(1):125-132. doi: 10.1002/cpt.2607.

View Publication
June, 2022

Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH

Naoumov NV, Brees D, Loeffler J, Chng E, Ren Y, Lopez P, Tai D, Lamle S, Sanyal AJ. J Hepatol. 2022 Jun 30:S0168-8278(22)00412-3. doi: 10.1016/j.jhep.2022.06.018.

View Publication
June, 2022

Current therapies and new developments in NASH

Dufour JF, Anstee QM, Bugianesi E, Harrison S, Loomba R, Paradis V, Tilg H, Wong VW, Zelber-Sagi S. Gut. 2022 Jun 16:gutjnl-2021-326874. doi: 10.1136/gutjnl-2021-326874.

View Publication
June, 2022

Noninvasive Diagnosis of Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis Using Machine Learning Methods: Comparative Study With Existing Quantitative Risk Scores

Wu Y, Yang X, Morris HL, Gurka MJ, Shenkman EA, Cusi K, Bril F, Donahoo WT. JMIR Med Inform. 2022 Jun 6;10(6):e36997. doi: 10.2196/36997.

View Publication
June, 2022

Breakthroughs in therapies for NASH and remaining challenges

Ratziu V, Francque S, Sanyal A. J Hepatol. 2022 Jun;76(6):1263-1278. doi: 10.1016/j.jhep.2022.04.002.

View Publication
June, 2022

A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation

Vujkovic M, Ramdas S, Lorenz KM, Guo X, Darlay R, Cordell HJ, He J, Gindin Y, Chung C, Myers RP, Schneider CV, Park J, Lee KM, Serper M, Carr RM, Kaplan DE, Haas ME, MacLean MT, Witschey WR, Zhu X, Tcheandjieu C, Kember RL, Kranzler HR, Verma A, Giri A, Klarin DM, Sun YV, Huang J, Huffman JE, Townsend Creasy K, Hand NJ, Liu CT, Long MT, Yao J, Budoff M, Tan J, Li X, Lin HJ, Chen YI, Taylor KD, Chang RK, Krauss RM, Vilarinho S, Brancale J, Nielsen JB, Locke AE, Jones MB, Verweij N, Baras A, Reddy KR, Neuschwander-Tetri BA, Schwimmer JB, Sanyal AJ, Chalasani N, Ryan KA, Mitchell BD, Gill D, Wells AD, Manduchi E, Saiman Y, Mahmud N, Miller DR, Reaven PD, Phillips LS, Muralidhar S, DuVall SL, Lee JS, Assimes TL, Pyarajan S, Cho K, Edwards TL, Damrauer SM, Wilson PW, Gaziano JM, O'Donnell CJ, Khera AV, Grant SFA, Brown CD, Tsao PS, Saleheen D, Lotta LA, Bastarache L, Anstee QM, Daly AK, Meigs JB, Rotter JI, Lynch JA; Regeneron Genetics Center; Geisinger-Regeneron DiscovEHR Collaboration; EPoS Consortium; VA Million Veteran Program, Rader DJ, Voight BF, Chang KM. Nat Genet. 2022 Jun 2. doi: 10.1038/s41588-022-01078-z.

View Publication
June, 2022

Clinical features and outcomes of NAFLD-related hepatocellular carcinoma – Authors’ reply

Tan DJH, Ng CH, Muthiah MD, Loomba R, Huang DQ. Lancet Oncol. 2022 Jun;23(6):e244. doi: 10.1016/S1470-2045(22)00265-0.

View Publication
June, 2022

African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population

Cavalcante LN, Porto J, Mazo D, Longatto-Filho A, Stefano JT, Lyra AC, Carrilho FJ, Reis RM, Alves VAF, Sanyal AJ, Oliveira CP. Ann Hepatol. 2022 Jun 13:100728. doi: 10.1016/j.aohep.2022.100728.

View Publication
June, 2022

Incidence of Type 2 Diabetes in Children With Nonalcoholic Fatty Liver Disease

Newton KP, Wilson LA, Crimmins NA, Fishbein MH, Molleston JP, Xanthakos SA, Behling C, Schwimmer JB; Nonalcoholic Steatohepatitis Clinical Research Network. Clin Gastroenterol Hepatol. 2022 Jun 13:S1542-3565(22)00556-0. doi: 10.1016/j.cgh.2022.05.028.

View Publication
June, 2022

Artificial Intelligence Improves Pathologist Agreement for Fibrosis Scores in Nonalcoholic Steatohepatitis Patients

Soon GST, Liu F, Leow WQ, Wee A, Wei L, Sanyal AJ. Clin Gastroenterol Hepatol. 2022 Jun 10:S1542-3565(22)00555-9. doi: 10.1016/j.cgh.2022.05.027.

View Publication
June, 2022

Hepatic Stellate Cell-Immune Interactions in NASH

Carter JK, Friedman SL. Front Endocrinol (Lausanne). 2022 Jun 9;13:867940. doi: 10.3389/fendo.2022.867940.

View Publication
June, 2022

Comorbidities in Recent-Onset Adult Type 1 Diabetes: A Comparison of German Cohorts

Zaharia OP, Lanzinger S, Rosenbauer J, Karges W, Müssig K, Meyhöfer SM, Burkart V, Hummel M, Raddatz D, Roden M, Szendroedi J, Holl RW. Front Endocrinol (Lausanne). 2022 Jun 3;13:760778. doi: 10.3389/fendo.2022.760778.

View Publication
May, 2022

Bone morphogenetic protein 2 is a new molecular target linked to non-alcoholic fatty liver disease with potential value as non-invasive screening tool

Marañón P, Fernández-García CE, Isaza SC, Rey E, Gallego-Durán R, Montero-Vallejo R, de Cía JR, Ampuero J, Romero-Gómez M, García-Monzón C, González-Rodríguez Á. Biomark Res. 2022 May 25;10(1):35. doi: 10.1186/s40364-022-00383-3.

View Publication
May, 2022

The Effect of Diabetes and Prediabetes on the Prevalence, Complications and Mortality in Non-alcoholic Fatty Liver Disease

Ng CH, Chan KE, Chin YH, Zeng RW, Tsai PC, Lim WH, Tan DJH, Khoo CM, Goh LH, Ling ZJ, Kulkarni A, Mak LL, Huang DQ, Chan M, Chew NW, Siddiqui MS, Sanyal AJ, Muthiah M. Clin Mol Hepatol. 2022 May 19. doi: 10.3350/cmh.2022.0096.

View Publication
May, 2022

Prevalence estimation of significant fibrosis due to NASH in Spain combining transient elastography and histology

Calleja JL, Rivera-Esteban J, Aller R, Hernández Conde M, Abad J, Pericàs JM, Gonzalo Benito H, Serra MÁ, Escudero A, Ampuero J, Lucena A, Sánchez Y, Arias-Loste MT, Iruzubieta P, Romero-Gómez M, Augustin S, Crespo J. Liver Int. 2022 May 28. doi: 10.1111/liv.15323.

View Publication
May, 2022

Changes in the gut microbiome associated with liver stiffness improvement in nonalcoholic steatohepatitis

Sharpton SR, Podlaha O, Chuang JC, Gindin Y, Myers RP, Loomba R. Therap Adv Gastroenterol. 2022 May 18;15:17562848221098243. doi: 10.1177/17562848221098243.

View Publication
May, 2022

Clinicians’ Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study

Vali Y, Eijk R, Hicks T, Jones WS, Suklan J, Holleboom AG, Ratziu V, Langendam MW, Anstee QM, Bossuyt PMM; LITMUS Investigators. J Clin Med. 2022 May 11;11(10):2707. doi: 10.3390/jcm11102707.

View Publication
May, 2022

Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD

Smirnova E, Muthiah MD, Narayan N, Siddiqui MS, Puri P, Luketic VA, Contos MJ, Idowu M, Chuang JC, Billin AN, Huss RS, Myers RP, Boyett S, Seneshaw M, Min HK, Mirshahi F, Sanyal AJ. Hepatology. 2022 May 13. doi: 10.1002/hep.32568.

View Publication
May, 2022

Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017-2018

Truong E, Yeo YH, Cook-Wiens G, Muthiah M, Yang JD, Sundaram V, Chang D, Todo T, Kim IK, Lu SC, Setiawan VW, Wong VWS, Harrison SA, Alkhouri N, Noureddin M. Hepatol Commun. 2022 May 9. doi: 10.1002/hep4.1981.

View Publication
May, 2022

Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease

Chew NWS, Ng CH, Muthiah MD, Sanyal AJ. Curr Atheroscler Rep. 2022 May 4. doi: 10.1007/s11883-022-01027-5.

View Publication
May, 2022

Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis

Sinakos E, Liava C, Loomba R. Ann Gastroenterol. 2022 May-Jun;35(3):213-225. doi: 10.20524/aog.2022.0704.

View Publication
May, 2022

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)

Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, Rinella ME, Vos MB, Younossi Z. Endocr Pract. 2022 May;28(5):528-562. doi: 10.1016/j.eprac.2022.03.010.

View Publication
May, 2022

NAFLD/NASH

Bugianesi E, Petta S. J Hepatol. 2022 May 2:S0168-8278(22)00081-2. doi: 10.1016/j.jhep.2022.02.006.

View Publication
May, 2022

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)

Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, Rinella ME, Vos MB, Younossi Z. Endocr Pract. 2022 May;28(5):528-562. doi: 10.1016/j.eprac.2022.03.010.

View Publication
May, 2022

Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis

Ng CH, Lim WH, Hui Lim GE, Hao Tan DJ, Syn N, Muthiah MD, Huang DQ, Loomba R. Clin Gastroenterol Hepatol. 2022 May 2:S1542-3565(22)00439-6. doi: 10.1016/j.cgh.2022.04.014.

View Publication
May, 2022

Response to: “Nonalcoholic fatty liver disease in diabetes: Overlooked or just ignored?”

Barb D, Cusi K. Obesity (Silver Spring). 2022 May;30(5):971-972. doi: 10.1002/oby.23422.

View Publication
May, 2022

Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH

Vilalta A, Gutiérrez JA, Chaves S, Hernández M, Urbina S, Hompesch M. Endocrinol Diabetes Metab. 2022 May;5(3):e00335. doi: 10.1002/edm2.335.

View Publication
April, 2022

A global view of the interplay between non-alcoholic fatty liver disease and diabetes.

Stefan N, Cusi K. Lancet Diabetes Endocrinol. 2022 Apr;10(4):284-296. doi: 10.1016/S2213-8587(22)00003-1.

View Publication
April, 2022

Impaired Hepatic Mitochondrial Capacity in Nonalcoholic Steatohepatitis Associated With Type 2 Diabetes.

Gancheva S, Kahl S, Pesta D, Mastrototaro L, Dewidar B, Strassburger K, Sabah E, Esposito I, Weiß J, Sarabhai T, Wolkersdorfer M, Fleming T, Nawroth P, Zimmermann M, Reichert AS, Schlensak M, Roden M. Diabetes Care. 2022 Apr 1;45(4):928-937. doi: 10.2337/dc21-1758.

View Publication
April, 2022

Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study.

Huang DQ, Fowler KJ, Liau J, Cunha GM, Louie AL, An JY, Bettencourt R, Jung J, Gitto Z, Hernandez C, Lopez SJ, Gupta H, Sirlin CB, Marks RM, Loomba R. Aliment Pharmacol Ther. 2022 Apr;55(7):820-827. doi: 10.1111/apt.16844.

View Publication
April, 2022

A nutrigenetic tool for precision dietary management of NAFLD deeming insulin resistance markers

Perez-Diaz-Del-Campo N, Riezu-Boj JI, Marin-Alejandre BA, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Milagro FI, Bugianesi E, Tur JA, Martinez JA, Abete I, Zulet MA. Panminerva Med. 2022 Apr 19. doi: 10.23736/S0031-0808.22.04590-6.

View Publication
April, 2022

Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science

Fouad Y, Palmer M, Chen M, Regev A, Banerjee R, Myers R, Riccio R, Torstenson R, Younes R, Arora PS, Landgren H, Karsdal MA, Blake M, Shapiro DA, Gruss HJ, Sheikh MY, Attia D, Bollipo S, Smith AD, Freilich B, Gish RG, Schuppan D. J Clin Transl Hepatol. 2022 Apr 28;10(2):374-382. doi: 10.14218/JCTH.2021.00408.

View Publication
April, 2022

Greater ectopic fat deposition and liver fibroinflammation, and lower skeletal muscle mass in people with type 2 diabetes

Waddell T, Bagur A, Cunha D, Thomaides-Brears H, Banerjee R, Cuthbertson DJ, Brown E, Cusi K, Després JP, Brady M. Obesity (Silver Spring). 2022 Apr 27. doi: 10.1002/oby.23425.

View Publication
March, 2022

Risk of liver-related events by age and diabetes duration in diabetic patients with non-alcoholic fatty liver disease.

Zhang X, Wong GL, Yip TC, Cheung JTK, Tse YK, Hui VW, Lin H, Lai JC, Chan HL, Kong AP, Wong VW. Hepatology. 2022 Mar 25. doi: 10.1002/hep.32476.

View Publication
March, 2022

Direct Comparison of Quantitative US versus Controlled Attenuation Parameter for Liver Fat Assessment Using MRI Proton Density Fat Fraction as the Reference Standard in Patients Suspected of Having NAFLD.

Jung J, Han A, Madamba E, Bettencourt R, Loomba RR, Boehringer AS, Andre MP, Erdman JW Jr, O'Brien WD Jr, Fowler KJ, Sirlin CB, Loomba R. Radiology. 2022 Mar 29:211131. doi: 10.1148/radiol.211131.

View Publication
March, 2022

Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease.

Tamaki N, Kurosaki M, Huang DQ, Loomba R. Hepatol Res. 2022 Mar 30. doi: 10.1111/hepr.13764.

View Publication
March, 2022

Non-Alcoholic fatty liver disease-associated DNA methylation and gene expression alterations in the livers of Collaborative Cross mice fed an obesogenic high-fat and high-sucrose diet.

Cusi K. J Clin Endocrinol Metab. 2022 Mar 25:dgac186. doi: 10.1210/clinem/dgac186.

View Publication
March, 2022

A Simple Test to Identify the Risk of NASH and Cirrhosis in People with Obesity or Diabetes: The Time to Screen is Now.

Cusi K. J Clin Endocrinol Metab. 2022 Mar 25:dgac186. doi: 10.1210/clinem/dgac186.

View Publication
March, 2022

Reliability of Histologic Assessment for NAFLD and Development of an Expanded NAFLD Activity Score.

Pai RK, Jairath V, Hogan M, Zou G, Adeyi OA, Anstee QM, Aqel BA, Behling C, Carey EJ, Clouston AD, Corey K, Feagan BG, Kleiner DE, Ma C, McFarlane SC, Noureddin M, Ratziu V, Valasek MA, Younossi ZM, Harrison SA, Loomba R. Hepatology. 2022 Mar 25. doi: 10.1002/hep.32475.

View Publication
March, 2022

Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.

Harrison SA, Abdelmalek MF, Neff G, Gunn N, Guy CD, Alkhouri N, Bashir MR, Freilich B, Kohli A, Khazanchi A, Sheikh MY, Leibowitz M, Rinella ME, Siddiqui MS, Kipnes M, Moussa SE, Younes ZH, Bansal M, Baum SJ, Borg B, Ruane PJ, Thuluvath PJ, Gottwald M, Khan M, Chen C, Melchor-Khan L, Chang W, DePaoli AM, Ling L, Lieu HD. Lancet Gastroenterol Hepatol. 2022 Mar 21:S2468-1253(22)00017-6. doi: 10.1016/S2468-1253(22)00017-6.

View Publication
March, 2022

Is lean non-alcoholic fatty liver disease a distinct entity?

Lin H, Wong VW. Hepatol Int. 2022 Mar 24. doi: 10.1007/s12072-022-10324-9.

View Publication
March, 2022

Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD.

Ampuero J, Gallego-Durán R, Maya-Miles D, Montero R, Gato S, Rojas Á, Gil A, Muñoz R, Romero-Gómez M. J Gastroenterol. 2022 Mar 24. doi: 10.1007/s00535-022-01860-0.

View Publication
March, 2022

Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis.

Ng CH, Muthiah MD, Xiao J, Chin YH, Lim G, Lim WH, Tay P, Tan DJH, Yong JN, Pan XH, Koh JWH, Chew N, Syn N, Tan E, Huang DQ, Siddiqui MS, Loomba R, Sanyal AJ, Noureddin M. Aliment Pharmacol Ther. 2022 Mar 14. doi: 10.1111/apt.16808.

View Publication
March, 2022

Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.

Deckmyn O, Poynard T, Bedossa P, Paradis V, Peta V, Pais R, Ratziu V, Thabut D, Brzustowski A, Gautier JF, Cacoub P, Valla D. Biomedicines. 2022 Mar 17;10(3):699. doi: 10.3390/biomedicines10030699.

View Publication
March, 2022

Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD).

Brandman D, Boyle M, McPherson S, Van Natta ML, Sanyal AJ, Kowdley K, Neuschwander-Tetri B, Chalasani N, Abdelmalek MF, Terrault NA, McCullough A, Bettencourt R, Caussy C, Kleiner DE, Behling C, Tonascia J, Anstee QM, Loomba R; Members of the Nonalcoholic Steatohepatitis Clinical Research Network. Aliment Pharmacol Ther. 2022 Mar 17. doi: 10.1111/apt.16874.

View Publication
March, 2022

Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.

Tan DJH, Ng CH, Lin SY, Pan XH, Tay P, Lim WH, Teng M, Syn N, Lim G, Yong JN, Quek J, Xiao J, Dan YY, Siddiqui MS, Sanyal AJ, Muthiah MD, Loomba R, Huang DQ. Lancet Oncol. 2022 Mar 4:S1470-2045(22)00078-X. doi: 10.1016/S1470-2045(22)00078-X.

View Publication
March, 2022

Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease.

Castillo-Leon E, Morris HL, Schoen C, Bilhartz J, McKiernan P, Miloh T, Palle S, Kabbany MN, Munoz B, Mospan AR, Rudolph B, Xanthakos SA, Vos MB, Target-Nash Investigators. Children (Basel). 2022 Mar 8;9(3):374. doi: 10.3390/children9030374.

View Publication
March, 2022

Meta-analysis: Prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease.

Zamani M, Alizadeh-Tabari S, Singh S, Loomba R. Aliment Pharmacol Ther. 2022 Mar 11. doi: 10.1111/apt.16879.

View Publication
March, 2022

NAFLD increases Risk of Carotid Atherosclerosis and Ischemic Stroke. An Updated Meta-Analysis with 135,602 Individuals.

Tang ASP, Chan KE, Quek J, Xiao J, Tay P, Teng M, Lee KS, Lin SY, Myint MZ, Tan B, Sharma VK, Tan DJH, Lim WH, Kaewdech A, Huang D, Chew NW, Siddiqui MS, Sanyal AJ, Muthiah M, Ng CH. Clin Mol Hepatol. 2022 Mar 2. doi: 10.3350/cmh.2021.0406.

View Publication
March, 2022

Global multi-stakeholder endorsement of the MAFLD definition.

Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, Sarin SK, Fabrellas N, Zelber-Sagi S, Fan JG, Shiha G, Targher G, Zheng MH, Chan WK, Vinker S, Kawaguchi T, Castera L, Yilmaz Y, Korenjak M, Spearman CW, Ungan M, Palmer M, El-Shabrawi M, Gruss HJ, Dufour JF, Dhawan A, Wedemeyer H, George J, Valenti L, Fouad Y, Romero-Gomez M, Eslam M; Global multi-stakeholder consensus on the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol. 2022 Mar 3:S2468-1253(22)00062-0. doi: 10.1016/S2468-1253(22)00062-0.

View Publication
March, 2022

A cholestatic pattern predicts major liver-related outcomes in patients with non-alcoholic fatty liver disease.

Pennisi G, Pipitone RM, Cabibi D, Enea M, Romero-Gomez M, Viganò M, Bugianesi E, Wong VW, Fracanzani AL, Sebastiani G, Berzigotti A, Di Salvo F, Giannone AG, La Mantia C, Lupo G, Porcasi R, Vernuccio F, Zito R, Di Marco V, Cammà C, Craxì A, de Ledinghen V, Grimaudo S, Petta S. Liver Int. 2022 Mar 4. doi: 10.1111/liv.15232.

View Publication
March, 2022

Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation.

Gallego-Durán R, Ampuero J, Pastor-Ramírez H, Álvarez-Amor L, Del Campo JA, Maya-Miles D, Montero-Vallejo R, Cárdenas-García A, Pareja MJ, Gato-Zambrano S, Millán R, Del Carmen Rico M, Luque-Sierra A, Gil-Gómez A, Rojas Á, Muñoz-Hernández R, García-Lozano M, Aller R, Andrade RJ, García-Monzón C, Andreola F, Martín F, Jalan R, Romero-Gómez M. Sci Rep. 2022 Mar 1;12(1):3418. doi: 10.1038/s41598-022-06614-9.

View Publication
March, 2022

Association of Obesity, Diabetes, and Alcohol Use With Liver Fibrosis Among US Adults With Hepatitis C Virus Infection.

Migdal AL, Jagannathan R, Qayed E, Cusi K, McCoy RG, Pasquel FJ, Miller LS. JAMA Netw Open. 2022 Mar 1;5(3):e2142282. doi: 10.1001/jamanetworkopen.2021.42282.

View Publication
March, 2022

Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project.

Sanyal AJ, Shankar SS, Calle RA, Samir AE, Sirlin CB, Sherlock SP, Loomba R, Fowler KJ, Dehn CA, Heymann H, Kamphaus TN. Nat Med. 2022 Mar;28(3):430-432. doi: 10.1038/s41591-021-01652-8.

View Publication
March, 2022

Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease

McGlinchey AJ, Govaere O, Geng D, Ratziu V, Allison M, Bousier J, Petta S, de Oliviera C, Bugianesi E, Schattenberg JM, Daly AK, Hyötyläinen T, Anstee QM, Orešič M. JHEP Rep. 2022 Mar 26;4(5):100477. doi: 10.1016/j.jhepr.2022.100477.

View Publication
March, 2022

JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk

Wyne KL, Litwin SE, Cusi K, Guyton JR. J Clin Lipidol. 2022 Mar-Apr;16(2):115-127. doi: 10.1016/j.jacl.2022.03.007.

View Publication
February, 2022

Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles.

Martínez-Arranz I, Bruzzone C, Noureddin M, Gil-Redondo R, Mincholé I, Bizkarguenaga M, Arretxe E, Iruarrizaga-Lejarreta M, Fernández-Ramos D, Lopitz-Otsoa F, Mayo R, Embade N, Newberry E, Mittendorf B, Izquierdo-Sánchez L, Smid V, Arnold J, Iruzubieta P, Pérez Castaño Y, Krawczyk M, Marigorta UM, Morrison MC, Kleemann R, Martín-Duce A, Hayardeny L, Vitek L, Bruha R, Aller de la Fuente R, Crespo J, Romero-Gomez M, Banales JM, Arrese M, Cusi K, Bugianesi E, Klein S, Lu SC, Anstee QM, Millet O, Davidson NO, Alonso C, Mato JM. Hepatology. 2022 Feb 26. doi: 10.1002/hep.32427.

View Publication
February, 2022

Nonalcoholic steatohepatitis is the most common indication for liver transplantation among the elderly: Data from the United States Scientific Registry of Transplant Recipients.

Stepanova M, Kabbara K, Mohess D, Verma M, Roche-Green A, AlQahtani S, Ong J, Burra P, Younossi ZM. Hepatol Commun. 2022 Feb 28. doi: 10.1002/hep4.1915.

View Publication
February, 2022

Differential fuel utilization in liver transplant recipients and its relationship with non-alcoholic fatty liver disease.

Siddiqui MS, Patel S, Forsgren M, Bui AT, Shen S, Syed T, Boyett S, Chen S, Sanyal AJ, Wolver S, Kirkman D, Celi FS, Bhati CS. Liver Int. 2022 Feb 7. doi: 10.1111/liv.15178.

View Publication
February, 2022

Factors Impacting Survival in Those Transplanted for NASH Cirrhosis: Data From the NailNASH Consortium.

Rinella ME, Satapathy SK, Brandman D, Smith C, Elwir S, Xia J, Gibson M, Figueredo C, Angirekula M, Vanatta JM, Sarwar R, Jiang Y, Gregory D, Agostini T, Ko J, Podila P, Gallo G, Watt KD, Siddiqui MS. Clin Gastroenterol Hepatol. 2022 Feb 18:S1542-3565(22)00184-7. doi: 10.1016/j.cgh.2022.02.028.

View Publication
February, 2022

Dual roles of B lymphocytes in mouse models of diet-induced nonalcoholic fatty liver disease.

Karl M, Hasselwander S, Zhou Y, Reifenberg G, Kim YO, Park KS, Ridder DA, Wang X, Seidel E, Hövelmeyer N, Straub BK, Li H, Schuppan D, Xia N. Hepatology. 2022 Feb 26. doi: 10.1002/hep.32428.

View Publication
February, 2022

Two-Step Strategy, FIB-4 Followed by Magnetic Resonance Elastography, for Detecting Advanced Fibrosis in NAFLD.

Tamaki N, Imajo K, Sharpton SR, Jung J, Sutter N, Kawamura N, Yoneda M, Valasek MA, Behling C, Sirlin CB, Kurosaki M, Izumi N, Nakajima A, Loomba R. Clin Gastroenterol Hepatol. 2022 Feb 2:S1542-3565(22)00077-5. doi: 10.1016/j.cgh.2022.01.023.

View Publication
February, 2022

Meaning of non-overlapping patients between the MAFLD and NAFLD definitions.

Chan WK, Wong VW. Liver Int. 2022 Feb;42(2):271-273. doi: 10.1111/liv.15142.

View Publication
February, 2022

Fatty Liver Through the Ages: Nonalcoholic Steatohepatitis.

Younossi ZM, Henry L. Endocr Pract. 2022 Feb;28(2):204-213. doi: 10.1016/j.eprac.2021.12.010. Epub 2021 Dec 22.

View Publication
February, 2022

Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.

Johnson K, Leary PJ, Govaere O, Barter MJ, Charlton SH, Cockell SJ, Tiniakos D, Zatorska M, Bedossa P, Brosnan MJ, Cobbold JF, Ekstedt M, Aithal GP, Clément K, Schattenberg JM, Boursier J, Ratziu V, Bugianesi E, Anstee QM, Daly AK; LITMUS Consortium Investigators; LITMUS Consortium Investigators. JHEP Rep. 2021 Nov 25;4(2):100409. doi: 10.1016/j.jhepr.2021.100409. eCollection 2022 Feb.

View Publication
February, 2022

Magnetic Resonance Elastography for the Clinical Risk Assessment of Fibrosis, Cirrhosis, and Portal Hypertension in Patients With NAFLD.

Natarajan Y, Loomba R. J Clin Exp Hepatol. 2022 Jan-Feb;12(1):174-179. doi: 10.1016/j.jceh.2021.08.002.

View Publication
January, 2022

Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD.

Tamaki N, Ajmera V, Loomba R. Nat Rev Endocrinol. 2022 Jan;18(1):55-66. doi: 10.1038/s41574-021-00584-0.

View Publication
January, 2022

Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study.

Tan EX, Lee JW, Jumat NH, Chan WK, Treeprasertsuk S, Goh GB, Fan JG, Song MJ, Charatcharoenwitthaya P, Duseja A, Imajo K, Nakajima A, Seki Y, Kasama K, Kakizaki S, Lesmana LA, Zheng KI, Zheng MH, Koh CJ, Ho KY, Goh KL, Wong VW, Dan YY. Metabolism. 2022 Jan;126:154911. doi: 10.1016/j.metabol.2021.154911.

View Publication
January, 2022

Hepatocyte-Specific Deletion of HIF2α Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation.

Foglia B, Sutti S, Cannito S, Rosso C, Maggiora M, Autelli R, Novo E, Bocca C, Villano G, Ramavath NN, Younes R, Tusa I, Rovida E, Pontisso P, Bugianesi E, Albano E, Parola M. Cell Mol Gastroenterol Hepatol. 2021 Oct 14:S2352-345X(21)00216-2. doi: 10.1016/j.jcmgh.2021.10.002.

View Publication
January, 2022

Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease.

Duseja A, Singh SP, Mehta M, Shalimar, Venkataraman J, Mehta V, Devadas K, Kar SK, Goyal O, Nagral A, Saigal S, Nijhawan S, Praharaj D, Shukla A, Sharma B, Narayanasamy K, Kumar P, Rao PN, Arora A, Mehta R, Asati P, Ranjan P, Koshy A, Alam S, Mukewar S, Mukewar S, Mohan Prasad VG, Rastogi M, Sanyal AJ. Metab Syndr Relat Disord. 2022 Jan 25. doi: 10.1089/met.2021.0104.

View Publication
January, 2022

Long-Term Effects of the Changes in Hepatic Steatosis Status on the Risk of Incident Type 2 Diabetes Mellitus: a 15-Year Community-Based Prospective Cohort Study.

Min Chung S, Kyu Kang M, Jung J, Sung Yoon J, Chang Won K, Woo Lee H, Loomba R, Gil Park J, Sung Moon J. Diabetes Res Clin Pract. 2022 Jan 18:109208. doi: 10.1016/j.diabres.2022.109208.

View Publication
January, 2022

Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis.

Di Maira G, Foglia B, Napione L, Turato C, Maggiora M, Sutti S, Novo E, Alvaro M, Autelli R, Colombatto S, Bussolino F, Carucci P, Gaia S, Rosso C, Biasiolo A, Pontisso P, Bugianesi E, Albano E, Marra F, Parola M, Cannito S. J Pathol. 2022 Jan 22. doi: 10.1002/path.5871.

View Publication
January, 2022

Derivation and validation of the NAFLD Cirrhosis Score (NCS) to distinguish bridging fibrosis from cirrhosis.

Labenz C, Toenges G, Zheng MH, Ding D, Myers RP, Galle PR, Armandi A, Ampuero J, Gómez MR, Bugianesi E, Anstee QM, Schattenberg JM. Eur J Intern Med. 2022 Jan 17:S0953-6205(21)00413-1. doi: 10.1016/j.ejim.2021.12.011.

View Publication
January, 2022

Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.

Boursier J, Hagström H, Ekstedt M, Moreau C, Bonacci M, Cure S, Ampuero J, Nasr P, Tallab L, Canivet CM, Kechagias S, Sánchez Y, Dincuff E, Lucena A, Roux M, Riou J, Trylesinski A, Romero-Gomez M. J Hepatol. 2022 Jan 18:S0168-8278(22)00002-2. doi: 10.1016/j.jhep.2021.12.031.

View Publication
January, 2022

Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis.

Pennisi G, Enea M, Romero-Gomez M, Viganò M, Bugianesi E, Wong VW, Fracanzani AL, Sebastiani G, Boursier J, Berzigotti A, Eslam M, Ampuero J, Benmassaoud A, La Mantia C, Mendoza YP, George J, Craxì A, Camma' C, de Ledinghen V, Petta S. Aliment Pharmacol Ther. 2022 Jan 5. doi: 10.1111/apt.16763.

View Publication
January, 2022

Placebo effect on progression and regression in NASH: Evidence from a meta-analysis.

Ng CH, Xiao J, Lim WH, Chin YH, Yong JN, Tan DJH, Tay P, Syn N, Foo R, Chan M, Chew N, Tan EX, Huang DQ, Dan YY, Tamaki N, Siddiqui MS, Sanyal AJ, Loomba R, Noureddin M, Muthiah MD. Hepatology. 2022 Jan 6. doi: 10.1002/hep.32315.

View Publication
December, 2021

NASHFit: of an exercise training program to reduce clotting risk in patients with NASH.

Stine JG, Schreibman IR, Faust AJ, Dahmus J, Stern B, Soriano C, Rivas G, Hummer B, Kimball SR, Geyer NR, Chinchilli VM, Loomba R, Schmitz K, Sciamanna C. Hepatology. 2021 Dec 10. doi: 10.1002/hep.32274.

View Publication
December, 2021

The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?

Lazarus JV, Mark HE, Villota-Rivas M, Palayew A, Carrieri P, Colombo M, Ekstedt M, Esmat G, George J, Marchesini G, Novak K, Ocama P, Ratziu V, Razavi H, Romero-Gómez M, Silva M, Spearman CW, Tacke F, Tsochatzis EA, Yilmaz Y, Younossi ZM, Wong VW, Zelber-Sagi S, Cortez-Pinto H, Anstee QM; NAFLD policy review collaborators. J Hepatol. 2021 Dec 8:S0168-8278(21)02168-1. doi: 10.1016/j.jhep.2021.10.025.

View Publication
December, 2021

Elevated liver enzymes and comorbidities in type 2 diabetes: Multicenter analysis of 51,645 patients of the DPV database.

Meyhöfer S, Eckert AJ, Hummel M, Laimer M, Roden M, Kress S, Seufert J, Meyhöfer SM, Holl RW. Diabetes Obes Metab. 2021 Dec 9. doi: 10.1111/dom.14616. Online ahead of print.PMID: 34882949 

View Publication
December, 2021

Comparative diagnostic performance of ultrasound shear wave elastography and magnetic resonance elastography for classifying fibrosis stage in adults with biopsy-proven nonalcoholic fatty liver disease.

Zhang YN, Fowler KJ, Boehringer AS, Montes V, Schlein AN, Covarrubias Y, Wolfson T, Hong CW, Valasek MA, Andre MP, Loomba R, Sirlin CB. Eur Radiol. 2021 Dec 2. doi: 10.1007/s00330-021-08369-9.

View Publication
December, 2021

An Observational Data Meta-Analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD.

Hui Lim GE, Tang A, Ng CH, Chin YH, Lim WH, Hao Tan DJ, Yong JN, Xiao J, Wen-Min Lee C, Chan M, Chew NW, Xuan Tan EX, Siddiqui MS, Huang D, Noureddin M, Sanyal AJ, Muthiah MD. Clin Gastroenterol Hepatol. 2021 Dec 3:S1542-3565(21)01276-3. doi: 10.1016/j.cgh.2021.11.038.

View Publication
December, 2021

Evaluation of a Stepped Care Approach to Manage Depression and Diabetes Distress in Patients with Type 1 Diabetes and Type 2 Diabetes: Results of a Randomized Controlled Trial (ECCE HOMO Study).

Schmitt A, Kulzer B, Reimer A, Herder C, Roden M, Haak T, Hermanns N. Psychother Psychosom. 2021 Dec 7:1-16. doi: 10.1159/000520319.

View Publication
December, 2021

The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality.

Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. Lancet. 2021 Dec 1:S0140-6736(21)01701-3. doi: 10.1016/S0140-6736(21)01701-3.

View Publication
December, 2021

Pharmacokinetic and pharmacodynamic bioequivalence between regular human insulin (rDNA origin) in 0.9% sodium chloride ready-to-use infusion 1 U/mL and 100 U/mL concentrate diluted to 1 U/mL in healthy males.

Hompesch M, Hawryluk A, Hernandez M, Uchil B, Wilmington A, Peterson L. Diabetes Obes Metab. 2021 Dec;23(12):2679-2686. doi: 10.1111/dom.14520.

View Publication
December, 2021

Editorial: evolution of GLP-1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity – authors’ reply.

Flint A, Andersen G, Hockings P, Plum-Mörschel L, Loomba R. Aliment Pharmacol Ther. 2021 Dec;54(11-12):1498. doi: 10.1111/apt.16669.

View Publication
December, 2021

Corrigendum to ‘Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis’ [J Hepatol 75 (2021) 865-878].

Pinyol R, Torrecilla S, Wang H, Montironi C, Piqué-Gili M, Torres-Martin M, Wei-Qiang L, Willoughby CE, Ramadori P, Andreu-Oller C, Taik P, Lee YA, Moeini A, Peix J, Faure-Dupuy S, Riedl T, Schuehle S, Oliveira CP, Alves VA, Boffetta P, Lachenmayer A, Roessler S, Minguez B, Schirmacher P, Dufour JF, Thung SN, Reeves HL, Carrilho FJ, Chang C, Uzilov AV, Heikenwalder M, Sanyal A, Friedman SL, Sia D, Llovet JM. J Hepatol. 2021 Dec;75(6):1515. doi: 10.1016/j.jhep.2021.09.014.

View Publication
December, 2021

Liver biopsy in the real world-reporting, expert concordance and correlation with a pragmatic clinical diagnosis.

Kim HP, Idowu MO, Mospan AR, Allmon AG, Roden M, Newsome P, Lok AS, Thuluvath PJ, Taunk J, Fried MW, Sanyal AJ, Barritt AS 4th; TARGET-NASH Investigators. Aliment Pharmacol Ther. 2021 Dec;54(11-12):1472-1480. doi: 10.1111/apt.16674.

View Publication
December, 2021

A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach.

Lazarus JV, Mark HE, Colombo M, Demaio S, Dillon JF, George J, Hagström H, Hocking S, Lee N, Nieuwenhuijsen MJ, Rinella ME, Romero-Gomez M, Soriano JB, Schattenberg JM, Tacke F, Tsochatzis EA, Valenti L, Zelber-Sagi S, Ashworth Dirac M, Huang TT. Aliment Pharmacol Ther. 2021 Dec 5. doi: 10.1111/apt.16720.

View Publication
December, 2021

A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy.

Guo F, Estévez-Vázquez O, Benedé-Ubieto R, Maya-Miles D, Zheng K, Gallego-Durán R, Rojas Á, Ampuero J, Romero-Gómez M, Philip K, Egbuniwe IU, Chen C, Simon J, Delgado TC, Martínez-Chantar ML, Sun J, Reissing J, Bruns T, Lamas-Paz A, Moral MGD, Woitok MM, Vaquero J, Regueiro JR, Liedtke C, Trautwein C, Bañares R, Cubero FJ, Nevzorova YA. Cancers (Basel). 2021 Dec 31;14(1):192. doi: 10.3390/cancers14010192.

View Publication
December, 2021

Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.

Govaere O, Petersen SK, Martinez-Lopez N, Wouters J, Van Haele M, Mancina RM, Jamialahmadi O, Bilkei-Gorzo O, Lassen PB, Darlay R, Peltier J, Palmer JM, Younes R, Tiniakos D, Aithal GP, Allison M, Vacca M, Göransson M, Berlinguer-Palmini R, Clark JE, Drinnan MJ, Yki-Järvinen H, Dufour JF, Ekstedt M, Francque S, Petta S, Bugianesi E, Schattenberg JM, Day CP, Cordell HJ, Topal B, Clément K, Romeo S, Ratziu V, Roskams T, Daly AK, Anstee QM, Trost M, Härtlova A. J Hepatol. 2021 Dec 20:S0168-8278(21)02254-6. doi: 10.1016/j.jhep.2021.12.012.

View Publication
December, 2021

Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population.

Graupera I, Thiele M, Serra-Burriel M, Caballeria L, Roulot D, Wong GL, Fabrellas N, Guha IN, Arslanow A, Expósito C, Hernández R, Aithal GP, Galle PR, Pera G, Wong VW, Lammert F, Ginès P, Castera L, Krag A; Investigators of the LiverScreen Consortium. Clin Gastroenterol Hepatol. 2021 Dec 29:S1542-3565(21)01358-6. doi: 10.1016/j.cgh.2021.12.034.

View Publication
December, 2021

Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study.

Fouqueray P, Bolze S, Dubourg J, Hallakou-Bozec S, Theurey P, Grouin JM, Chevalier C, Gluais-Dagorn P, Moller DE, Cusi K. Cell Rep Med. 2021 Dec 21;2(12):100474. doi: 10.1016/j.xcrm.2021.100474.

View Publication
November, 2021

Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis.

Loomba R, Ratziu V, Harrison SA; NASH Clinical Trial Design International Working Group. Gastroenterology. 2021 Nov 22:S0016-5085(21)03795-1. doi: 10.1053/j.gastro.2021.10.051.

View Publication
November, 2021

Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases.

Gallego-Durán R, Montero-Vallejo R, Maya-Miles D, Lucena A, Martin F, Ampuero J, Romero-Gómez M. Front Immunol. 2021 Nov 24;12:667354. doi: 10.3389/fimmu.2021.667354.

View Publication
November, 2021

Evaluating Outcomes Related to Donor and Recipient Metabolic Environment: Macrosteatotic Allograft and Nonalcoholic Steatohepatitis.

Brubaker AL, Loomba R. Liver Transpl. 2021 Nov 22. doi: 10.1002/lt.26371.

View Publication
November, 2021

Fatty Liver Disease: Diagnosis and Stratification.

Saiman Y, Duarte-Rojo A, Rinella ME. Annu Rev Med. 2021 Nov 22. doi: 10.1146/annurev-med-042220-020407.

View Publication
November, 2021

Outcomes of Non-alcoholic Steatohepatitis following Liver Transplantation. An Updated Meta-analysis and Systematic Review.

Yong JN, Lim WH, Ng CH, Hao Tan DJ, Xiao J, Lin Tay PW, Lin SY, Syn N, Chew N, Nah B, Dan YY, Huang DQ, Xuan Tan EX, Sanyal AJ, Noureddin M, Siddiqui MS, Muthiah MD. Clin Gastroenterol Hepatol. 2021 Nov 18:S1542-3565(21)01226-X. doi: 10.1016/j.cgh.2021.11.014.

View Publication
November, 2021

Differences in the prevalence of erectile dysfunction between novel subgroups of recent-onset diabetes.

Maalmi H, Herder C, Bönhof GJ, Strassburger K, Zaharia OP, Rathmann W, Burkart V, Szendroedi J, Roden M, Ziegler D; GDS Group. Diabetologia. 2021 Nov 20. doi: 10.1007/s00125-021-05607-z.

View Publication
November, 2021

Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.

Rinella M, Dufour JF, Anstee QM, Goodman Z, Younossi Z, Harrison SA, Loomba R, Sanyal AJ, Bonacci M, Trylesinski A, Natha M, Shringarpure R, Granston T, Venugopal A, Ratziu V. J Hepatol. 2021 Nov 15:S0168-8278(21)02177-2. doi: 10.1016/j.jhep.2021.10.029.

View Publication
November, 2021

Liquid biomarkers for fibrotic NASH – progress in a complex field.

Golabi P, Paik JM, Eberly K, de Avila L, Alqahtani SA, Younossi ZM. Ann Hepatol. 2021 Nov 18;27(1):100556. doi: 10.1016/j.aohep.2021.100556.

View Publication
November, 2021

Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C.

Golabi P, Paik JM, Eberly K, de Avila L, Alqahtani SA, Younossi ZM. Ann Hepatol. 2021 Nov 18;27(1):100556. doi: 10.1016/j.aohep.2021.100556.

View Publication
November, 2021

Noninvasive Risk Stratification for Nonalcoholic Fatty Liver Disease Among Living Liver Donor Candidates: A Proposed Algorithm.

Danis N, Weeks SR, Kim A, Baghdadi A, Ghadimi M, Kamel IR, Saberi B, Woreta T, Garonzik-Wang J, Philosophe B, Gurakar A, Loomba R. Liver Transpl. 2021 Nov 9. doi: 10.1002/lt.26365.

View Publication
November, 2021

The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative Review.

Armandi A, Rosso C, Caviglia GP, Ribaldone DG, Bugianesi E. Front Endocrinol (Lausanne). 2021 Nov 10;12:716533. doi: 10.3389/fendo.2021.716533.

View Publication
November, 2021

Comparison of patient characteristics between East Asian and non-East Asian patients with insulin autoimmune syndrome.

Oest L, Roden M, Müssig K. Clin Endocrinol (Oxf). 2021 Nov 14. doi: 10.1111/cen.14634.

View Publication
November, 2021

Physical fitness and cardiovascular risk factors in the novel diabetes subgroups.

Saatmann N, Zaharia OP, Strassburger K, Pesta DH, Burkart V, Szendroedi J, Gerdes N, Kelm M, Roden M. J Clin Endocrinol Metab. 2021 Nov 8:dgab810. doi: 10.1210/clinem/dgab810.

View Publication
November, 2021

Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global NASH/NAFLD Registry.

Younossi ZM, Yilmaz Y, Yu ML, Wai-Sun Wong V, Fernandez MC, Isakov VA, Duseja AK, Mendez-Sanchez N, Eguchi Y, Bugianesi E, Burra P, George J, Fan JG, Papatheodoridis GV, Chan WK, Alswat K, Saeed HS, Singal AK, Romero-Gomez M, Gordon SC, Roberts SK, El Kassas M Sr, Kugelmas M, Ong JP, Alqahtani S, Ziayee M, Lam B, Younossi I, Racila A, Henry L, Stepanova M; Global NASH Council. Clin Gastroenterol Hepatol. 2021 Nov 9:S1542-3565(21)01183-6. doi: 10.1016/j.cgh.2021.11.004.

View Publication
November, 2021

Utility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients.

Mowry CJ, Alonso C, Iruarrizaga-Lejarreta M, Ortiz P, Levitsky J, Rinella M. Transplant Direct. 2021 Nov 5;7(12):e784. doi: 10.1097/TXD.0000000000001227.

View Publication
November, 2021

Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.

Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E, Abdelmalek MF, Harrison SA, Loomba R, Mantzoros CS, Bugianesi E, Eckel RH, Kaplan LM, El-Serag HB, Cusi K. Gastroenterology. 2021 Nov;161(5):1657-1669. doi: 10.1053/j.gastro.2021.07.049.

View Publication
November, 2021

EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.

Ratziu V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, Denham D, Kayali Z, Sheikh A, Kowdley KV, Desta T, Elkhashab M, DeGrauw J, Goodwin B, Ahmad A, Adda N. J Hepatol. 2021 Nov 2:S0168-8278(21)02155-3. doi: 10.1016/j.jhep.2021.10.018.

View Publication
November, 2021

The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma.

Lewinska M, Santos-Laso A, Arretxe E, Alonso C, Zhuravleva E, Jimenez-Agüero R, Eizaguirre E, Pareja MJ, Romero-Gómez M, Arrese M, Suppli MP, Knop FK, Oversoe SK, Villadsen GE, Decaens T, Carrilho FJ, de Oliveira CP, Sangro B, Macias RIR, Banales JM, Andersen JB. EBioMedicine. 2021 Nov;73:103661. doi: 10.1016/j.ebiom.2021.103661.

View Publication
November, 2021

The peroxisomal transporter ABCD3 plays a major role in hepatic dicarboxylic fatty acid metabolism and lipid homeostasis.

Ranea-Robles P, Chen H, Stauffer B, Yu C, Bhattacharya D, Friedman SL, Puchowicz M, Houten SM. J Inherit Metab Dis. 2021 Nov;44(6):1419-1433. doi: 10.1002/jimd.12440.

View Publication
November, 2021

Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis.

Zhu C, Kim K, Wang X, Bartolome A, Salomao M, Dongiovanni P, Meroni M, Graham MJ, Yates KP, Diehl AM, Schwabe RF, Tabas I, Valenti L, Lavine JE, Pajvani UB.
Sci Transl Med. 2018 Nov 21;10(468). pii: eaat0344. doi: 10.1126/scitranslmed.aat0344.

View Publication
October, 2021

Prediabetes and risk of mortality, diabetes-related complications and comorbidities: umbrella review of meta-analyses of prospective studies.

Schlesinger S, Neuenschwander M, Barbaresko J, Lang A, Maalmi H, Rathmann W, Roden M, Herder C. Diabetologia. 2021 Oct 31. doi: 10.1007/s00125-021-05592-3.   

View Publication
October, 2021

Dietary palmitate and oleate differently modulate insulin sensitivity in human skeletal muscle.

Sarabhai T, Koliaki C, Mastrototaro L, Kahl S, Pesta D, Apostolopoulou M, Wolkersdorfer M, Bönner AC, Bobrov P, Markgraf DF, Herder C, Roden M. Diabetologia. 2021 Oct 26. doi: 10.1007/s00125-021-05596-z.

View Publication
October, 2021

Advancing the global public health agenda for NAFLD: a consensus statement.

Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, Cortez-Pinto H, Crespo J, Cusi K, Dirac MA, Francque S, George J, Hagström H, Huang TT, Ismail MH, Kautz A, Sarin SK, Loomba R, Miller V, Newsome PN, Ninburg M, Ocama P, Ratziu V, Rinella M, Romero D, Romero-Gómez M, Schattenberg JM, Tsochatzis EA, Valenti L, Wong VW, Yilmaz Y, Younossi ZM, Zelber-Sagi S; NAFLD Consensus Consortium. Nat Rev Gastroenterol Hepatol. 2021 Oct 27. doi: 10.1038/s41575-021-00523-4.

View Publication
October, 2021

Repositioning of a novel GABA-B receptor agonist, AZD3355 (Lesogaberan), for the treatment of non-alcoholic steatohepatitis.

Bhattacharya D, Becker C, Readhead B, Goossens N, Novik J, Fiel MI, Cousens LP, Magnusson B, Backmark A, Hicks R, Dudley JT, Friedman SL. Sci Rep. 2021 Oct 21;11(1):20827. doi: 10.1038/s41598-021-99008-2.

View Publication
October, 2021

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.

Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, Loomba R, Harrison SA, Balabanska R, Mateva L, Lanthier N, Alkhouri N, Moreno C, Schattenberg JM, Stefanova-Petrova D, Vonghia L, Rouzier R, Guillaume M, Hodge A, Romero-Gómez M, Huot-Marchand P, Baudin M, Richard MP, Abitbol JL, Broqua P, Junien JL, Abdelmalek MF; NATIVE Study Group. N Engl J Med. 2021 Oct 21;385(17):1547-1558. doi: 10.1056/NEJMoa2036205.

View Publication
October, 2021

Evolution of Fatty Liver Disease and Relationship With Lipoproteins and Clinical Outcomes in Hepatitis B/Human Immunodeficiency Virus Coinfection.

Khalili M, King WC, Kleiner DE, Chung RT, Bhan AK, Ghany MG, Sulkowski MS, Lisker-Melman M, Jain MK, Janssen HLA, Hinerman AS, Sanyal AJ, Sterling RK. Clin Infect Dis. 2021 Oct 25:ciab764. doi: 10.1093/cid/ciab764.

View Publication
October, 2021

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.

Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, Loomba R, Harrison SA, Balabanska R, Mateva L, Lanthier N, Alkhouri N, Moreno C, Schattenberg JM, Stefanova-Petrova D, Vonghia L, Rouzier R, Guillaume M, Hodge A, Romero-Gómez M, Huot-Marchand P, Baudin M, Richard MP, Abitbol JL, Broqua P, Junien JL, Abdelmalek MF; NATIVE Study Group. N Engl J Med. 2021 Oct 21;385(17):1547-1558. doi: 10.1056/NEJMoa2036205.

View Publication
October, 2021

Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.

Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, Loomba R, Chalasani N, Kowdley K, Hameed B, Wilson LA, Yates KP, Belt P, Lazo M, Kleiner DE, Behling C, Tonascia J; NASH Clinical Research Network (CRN). N Engl J Med. 2021 Oct 21;385(17):1559-1569. doi: 10.1056/NEJMoa2029349.

View Publication
October, 2021

Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis.

Sanyal AJ, Anstee QM, Trauner M, Lawitz EJ, Abdelmalek MF, Ding D, Han L, Jia C, Huss RS, Chung C, Wong VW, Okanoue T, Romero-Gomez M, Muir AJ, Afdhal NH, Bosch J, Goodman Z, Harrison SA, Younossi ZM, Myers RP. Hepatology. 2021 Oct 18. doi: 10.1002/hep.32204.

View Publication
October, 2021

Glucose-lowering drugs and outcome from COVID-19 among patients with type 2 diabetes mellitus: a population-wide analysis in Hong Kong.

Luk AOY, Yip TCF, Zhang X, Kong APS, Wong VW, Ma RCW, Wong GL. BMJ Open. 2021 Oct 20;11(10):e052310. doi: 10.1136/bmjopen-2021-052310.

View Publication
October, 2021

Diagnostic accuracy of two-dimensional shear wave elastography and transient elastography in nonalcoholic fatty liver disease.

Sharpton SR, Tamaki N, Bettencourt R, Madamba E, Jung J, Liu A, Behling C, Valasek MA, Loomba R. Therap Adv Gastroenterol. 2021 Oct 8;14:17562848211050436. doi: 10.1177/17562848211050436. eCollection 2021.

View Publication
October, 2021

The Impact of NASH to Liver Transplantations With Hepatocellular Carcinoma in the United States.

Younossi ZM, Harring M, Younossi Y, Ong JP, Alqahtani SA, Stepanova M. Clin Gastroenterol Hepatol. 2021 Oct 16:S1542-3565(21)01131-9. doi: 10.1016/j.cgh.2021.10.018.

View Publication
October, 2021

Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial.

Ratziu V, de Guevara L, Safadi R, Poordad F, Fuster F, Flores-Figueroa J, Arrese M, Fracanzani AL, Ben Bashat D, Lackner K, Gorfine T, Kadosh S, Oren R, Halperin M, Hayardeny L, Loomba R, Friedman S; ARREST investigator study group, Sanyal AJ. Nat Med. 2021 Oct;27(10):1825-1835. doi: 10.1038/s41591-021-01495-3.

View Publication
October, 2021

Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis.

Sanyal AJ, Anstee QM, Trauner M, Lawitz EJ, Abdelmalek MF, Ding D, Han L, Jia C, Huss RS, Chung C, Wong VW, Okanoue T, Romero-Gomez M, Muir AJ, Afdhal NH, Bosch J, Goodman Z, Harrison SA, Younossi ZM, Myers RP. Hepatology. 2021 Oct 18. doi: 10.1002/hep.32204.

View Publication
October, 2021

Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis.

Sanyal AJ, Anstee QM, Trauner M, Lawitz EJ, Abdelmalek MF, Ding D, Han L, Jia C, Huss RS, Chung C, Wong VW, Okanoue T, Romero-Gomez M, Muir AJ, Afdhal NH, Bosch J, Goodman Z, Harrison SA, Younossi ZM, Myers RP. Hepatology. 2021 Oct 18. doi: 10.1002/hep.32204.

View Publication
October, 2021

Targeting epigenetically maladapted vascular niche alleviates liver fibrosis in nonalcoholic steatohepatitis.

Zhang H, Ma Y, Cheng X, Wu D, Huang X, Chen B, Ren Y, Jiang W, Tang X, Bai T, Chen Y, Zhao Y, Zhang C, Xiao X, Liu J, Deng Y, Ye T, Chen L, Liu HM, Friedman SL, Chen L, Ding BS, Cao Z. Sci Transl Med. 2021 Oct 6;13(614):eabd1206. doi: 10.1126/scitranslmed.abd1206.

View Publication
October, 2021

Asian perspective on NAFLD-associated HCC.

Yip TC, Lee HW, Chan WK, Wong GL, Wong VW. J Hepatol. 2021 Oct 4:S0168-8278(21)02086-9. doi: 10.1016/j.jhep.2021.09.024.

View Publication
October, 2021

Association of genetic variations with NAFLD in lean individuals.

Lin H, Wong GL, Whatling C, Chan AW, Leung HH, Tse CH, Shu SS, Chim AM, Lai JC, Yip TC, Wong VW. Liver Int. 2021 Oct 5. doi: 10.1111/liv.15078.

View Publication
September, 2021

Randomized clinical trial: Semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging.

Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M, Vogl T, Loomba R, Plum-Mörschel L. Aliment Pharmacol Ther. 2021 Sep 27. doi: 10.1111/apt.16608.

View Publication
September, 2021

Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease.

Barb D, Repetto EM, Stokes ME, Shankar SS, Cusi K. Obesity (Silver Spring). 2021 Sep 23. doi: 10.1002/oby.23263.

View Publication
September, 2021

A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Non-alcoholic Fatty Liver Disease.

Kai Toh JZ, Pan XH, Lin Tay PW, Ng CH, Yong JN, Xiao J, Koh JH, Tan EY, Xuan Tan EX, Dan YY, Loh PH, Foo R, Chew NW, Sanyal AJ, Muthiah MD, Siddiqui MS. Clin Gastroenterol Hepatol. 2021 Sep 21:S1542-3565(21)01035-1. doi: 10.1016/j.cgh.2021.09.021.

View Publication
September, 2021

Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review.

Schattenberg JM, Anstee QM, Caussy C, Bugianesi E, Popovic B. Expert Rev Gastroenterol Hepatol. 2021 Sep 21:1-14. doi: 10.1080/17474124.2021.1974295.

View Publication
September, 2021

Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.

Cusi K, Alkhouri N, Harrison SA, Fouqueray P, Moller DE, Hallakou-Bozec S, Bolze S, Grouin JM, Jeannin Megnien S, Dubourg J, Ratziu V. Lancet Gastroenterol Hepatol. 2021 Sep 21:S2468-1253(21)00300-9. doi: 10.1016/S2468-1253(21)00300-9.

View Publication
September, 2021

Cross-Talk Between Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease: Implications for Future Trial Design.

Pellicori P, Vaduganathan M, Ferreira OP, Zannad F, Sanyal AJ. Diabetes Metab. 2021 Sep 17:101281. doi: 10.1016/j.diabet.2021.101281.

View Publication
September, 2021

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease.

Nakajima A, Eguchi Y, Yoneda M, Imajo K, Tamaki N, Suganami H, Nojima T, Tanigawa R, Iizuka M, Iida Y, Loomba R. Aliment Pharmacol Ther. 2021 Sep 16. doi: 10.1111/apt.16596.

View Publication
September, 2021

What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?

Alkhouri N, Tincopa M, Loomba R, Harrison SA. Hepatol Commun. 2021 Sep 9. doi: 10.1002/hep4.1814.

View Publication
September, 2021

MRE plus FIB-4 (MEFIB) versus FAST in detection of candidates for pharmacological treatment of NASH-related fibrosis.

Tamaki N, Imajo K, Sharpton S, Jung J, Kawamura N, Yoneda M, Valasek MA, Behling C, Sirlin CB, Nakajima A, Loomba R. Hepatology. 2021 Sep 8. doi: 10.1002/hep.32145.

View Publication
September, 2021

Inflammatory and fibrotic mechanisms in NAFLD-Implications for new treatment strategies.

Lee YA, Friedman SL. J Intern Med. 2021 Sep 26. doi: 10.1111/joim.13380.

View Publication
September, 2021

Fatty Pancreas Is Independently Associated With Subsequent Diabetes Mellitus Development: A 10-Year Prospective Cohort Study.

Chan TT, Tse YK, Lui RN, Wong GL, Chim AM, Kong AP, Woo J, Yeung DK, Abrigo JM, Chu WC, Wong VW, Tang RS. Clin Gastroenterol Hepatol. 2021 Sep 25:S1542-3565(21)01041-7. doi: 10.1016/j.cgh.2021.09.027.

View Publication
August, 2021

A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.

Bosch J, Chung C, Carrasco-Zevallos OM, Harrison SA, Abdelmalek MF, Shiffman ML, Rockey DC, Shanis Z, Juyal D, Pokkalla H, Le QH, Resnick M, Montalto M, Beck AH, Wapinski I, Han L, Jia C, Goodman Z, Afdhal N, Myers RP, Sanyal AJ. Hepatology. 2021 Aug 1. doi: 10.1002/hep.32087.

View Publication
July, 2021

Hepatic Fat Reduction Due to Resmetirom in Patients with Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life.

Younossi ZM, Stepanova M, Taub RA, Barbone JM, Harrison SA. Clin Gastroenterol Hepatol. 2021 Jul 27:S1542-3565(21)00821-1. doi: 10.1016/j.cgh.2021.07.039.

View Publication
July, 2021

TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial.

Loomba R, Mohseni R, Lucas KJ, Gutierrez JA, Perry RG, Trotter JF, Rahimi RS, Harrison SA, Ajmera V, Wayne JD, O'Farrell M, McCulloch W, Grimmer K, Rinella M, Wai-Sun Wong V, Ratziu V, Gores GJ, Neuschwander-Tetri BA, Kemble G. Gastroenterology. 2021 Jul 20:S0016-5085(21)03276-5. doi: 10.1053/j.gastro.2021.07.025.

View Publication
July, 2021

Novel Antidiabetic Strategies and Diabetologists’ Views in Nonalcoholic Steatohepatitis.

Kahl S, Pützer J, Roden M. Semin Liver Dis. 2021 Jul 21. doi: 10.1055/s-0041-1732354.

View Publication
July, 2021

Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis.

Younossi ZM, Stepanova M, Nader F, Loomba R, Anstee QM, Ratziu V, Harrison S, Sanyal AJ, Schattenberg JM, Barritt AS, Noureddin M, Bonacci M, Cawkwell G, Wong B, Rinella M; REGENERATE Study Investigators. Clin Gastroenterol Hepatol. 2021 Jul 15:S1542-3565(21)00751-5. doi: 10.1016/j.cgh.2021.07.020.

View Publication
July, 2021

Risk difference of liver-related and cardiovascular events by liver fibrosis status in nonalcoholic fatty liver disease.

Tamaki N, Higuchi M, Kurosaki M, Loomba R, Izumi N; MRCH Liver Study Group, Inada K, Kirino S, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Takahashi Y, Tsuchiya K, Nakanishi H, Itakura J. Clin Gastroenterol Hepatol. 2021 Jul 16:S1542-3565(21)00752-7. doi: 10.1016/j.cgh.2021.07.021.

View Publication
July, 2021

Emerging role of genomic analysis in clinical evaluation of lean individuals with NAFLD.

Vilarinho S, Ajmera V, Zheng M, Loomba R. Hepatology. 2021 Jul 7. doi: 10.1002/hep.32047.

View Publication
July, 2021

Outcomes and potential surrogate markers for future clinical trials of non-alcoholic steatohepatitis cirrhosis.

Rivera-Esteban J, Armandi A, Augustin S, Bugianesi E.Liver Int. 2021 Jul 9. doi: 10.1111/liv.15013.

View Publication
July, 2021

PPAR-γ-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH.

Gastaldelli A, Sabatini S, Carli F, Gaggini M, Bril F, Belfort-DeAguiar R, Positano V, Barb D, Kadiyala S, Harrison S, Cusi K. Liver Int. 2021 Jul 5. doi: 10.1111/liv.15005.

View Publication
July, 2021

Preparing for the NASH epidemic: A call to action.

Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, Harrison SA, Mantzoros C, Pfotenhauer K, Klein S, Eckel RH, Kruger D, El-Serag H, Cusi K. Metabolism. 2021 Jul 6:154822. doi: 10.1016/j.metabol.2021.154822.

View Publication
July, 2021

A Global Survey of Physicians Knowledge About Non-alcoholic Fatty Liver Disease.

Younossi ZM, Ong JP, Takahashi H, Yilmaz Y, Eguchi Y, El Kassas M, Buti M, Diago M, Zheng MH, Fan JG, Yu ML, Wai-Sun Wong V, Alswat K, Chan WK, Mendez-Sanchez N, Burra P, Bugianesi E, Duseja AK, George J, Papatheodoridis GV, Saeed H, Castera L, Arrese M, Kugelmas M, Romero-Gomez M, Alqahtani S, Ziayee M, Lam B, Younossi I, Racila A, Henry L, Stepanova M; Global NASH Council. Clin Gastroenterol Hepatol. 2021 Jul 3:S1542-3565(21)00719-9. doi: 10.1016/j.cgh.2021.06.048.

View Publication
July, 2021

TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial.

Loomba R, Mohseni R, Lucas KJ, Gutierrez JA, Perry RG, Trotter JF, Rahimi RS, Harrison SA, Ajmera V, Wayne JD, O'Farrell M, McCulloch W, Grimmer K, Rinella M, Wai-Sun Wong V, Ratziu V, Gores GJ, Neuschwander-Tetri BA, Kemble G. 
Gastroenterology. 2021 Jul 20:S0016-5085(21)03276-5. doi: 10.1053/j.gastro.2021.07.025.

View Publication
June, 2021

Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes.

Bril F, McPhaul MJ, Kalavalapalli S, Lomonaco R, Barb D, Gray ME, Shiffman D, Rowland CM, Cusi K. J Clin Endocrinol Metab. 2021 Jun 30:dgab417. doi: 10.1210/clinem/dgab417.

View Publication
June, 2021

Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis.

Yu J, Zhu C, Wang X, Kim K, Bartolome A, Dongiovanni P, Yates KP, Valenti L, Carrer M, Sadowski T, Qiang L, Tabas I, Lavine JE, Pajvani UB. Sci Transl Med. 2021 Jun 23;13(599):eabe1692. doi: 10.1126/scitranslmed.abe1692.

View Publication
June, 2021

Defining comprehensive models of care for NAFLD.

Lazarus JV, Anstee QM, Hagström H, Cusi K, Cortez-Pinto H, Mark HE, Roden M, Tsochatzis EA, Wong VW, Younossi ZM, Zelber-Sagi S, Romero-Gómez M, Schattenberg JM. Nat Rev Gastroenterol Hepatol. 2021 Jun 25. doi: 10.1038/s41575-021-00477-7.

View Publication
June, 2021

Alterations in bile acid metabolizing gut microbiota and specific bile acid genes as a precision medicine to subclassify NAFLD.

Jiao N, Loomba R, Yang ZH, Wu D, Fang S, Bettencourt R, Lan P, Zhu R, Zhu L. Physiol Genomics. 2021 Jun 21. doi: 10.1152/physiolgenomics.00011.2021.

View Publication
June, 2021

Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease.

Zhou YJ, Gao F, Liu WY, Wong GL, Mahadeva S, Raihan Nik Mustapha N, Wang XD, Chan WK, Wong VW, Zheng MH. Aliment Pharmacol Ther. 2021 Jun 21. doi: 10.1111/apt.16487.

View Publication
June, 2021

Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes.

Dayton KA, Bril F, Barb D, Lai J, Kalavalapalli S, Cusi K. PLoS One. 2021 Jun 2;16(6):e0251449. doi: 10.1371/journal.pone.0251449.

View Publication
June, 2021

Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.

Younes R, Caviglia GP, Govaere O, Rosso C, Armandi A, Sanavia T, Pennisi G, Liguori A, Francione P, Gallego-Durán R, Ampuero J, Garcia Blanco MJ, Aller R, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, Pareja MJ, Zaki MYW, Grieco A, Fracanzani AL, Valenti L, Miele L, Fariselli P, Petta S, Romero-Gomez M, Anstee QM, Bugianesi E. J Hepatol. 2021 Jun 3:S0168-8278(21)00343-3. doi: 10.1016/j.jhep.2021.05.008.

View Publication
June, 2021

Natural history of NASH.

Armandi A, Bugianesi E. Liver Int. 2021 Jun;41 Suppl 1:78-82. doi: 10.1111/liv.14910.

View Publication
June, 2021

Non-alcoholic fatty liver disease in type 2 diabetes – A specific entity?

Schröder B, Kahl S, Roden M. Liver Int. 2021 Jun;41 Suppl 1:105-111. doi: 10.1111/liv.14846.

View Publication
June, 2021

Consensus scoring systems for nonalcoholic fatty liver disease: an unmet clinical need.

Zhou YJ, Wong VW, Zheng MH. Hepatobiliary Surg Nutr. 2021 Jun;10(3):388-390. doi: 10.21037/hbsn-21-80.

View Publication
June, 2021

New drugs for NASH.

Albhaisi SAM, Sanyal AJ. Liver Int. 2021 Jun;41 Suppl 1:112-118. doi: 10.1111/liv.14844.

View Publication
June, 2021

Management of NAFLD patients with advanced fibrosis.

Maya-Miles D, Ampuero J, Gallego-Durán R, Dingianna P, Romero-Gómez M. Liver Int. 2021 Jun;41 Suppl 1:95-104. doi: 10.1111/liv.14847.PMID: 34155801

View Publication
June, 2021

Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study.

Barritt AS, Watkins S, Gitlin N, Klein S, Lok AS, Loomba R, Schoen C, Reddy KR, Trinh HN, Mospan AR, Vos MB, Weiss LM, Cusi K, Neuschwander-Tetri BA, Sanyal AJ. Hepatol Commun. 2021 Feb 21;5(6):938-946. doi: 10.1002/hep4.1689. eCollection 2021 Jun.

View Publication
June, 2021

Non-alcoholic fatty liver disease.

Powell EE, Wong VW, Rinella M. Lancet. 2021 Jun 5;397(10290):2212-2224. doi: 10.1016/S0140-6736(20)32511-3.

View Publication
June, 2021

Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes.

Dayton KA, Bril F, Barb D, Lai J, Kalavalapalli S, Cusi K. PLoS One. 2021 Jun 2;16(6):e0251449. doi: 10.1371/journal.pone.0251449.

View Publication
June, 2021

Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.

Younes R, Caviglia GP, Govaere O, Rosso C, Armandi A, Sanavia T, Pennisi G, Liguori A, Francione P, Gallego-Durán R, Ampuero J, Garcia Blanco MJ, Aller R, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, Pareja MJ, Zaki MYW, Grieco A, Fracanzani AL, Valenti L, Miele L, Fariselli P, Petta S, Romero-Gomez M, Anstee QM, Bugianesi E. J Hepatol. 2021 Jun 3:S0168-8278(21)00343-3. doi: 10.1016/j.jhep.2021.05.008.

View Publication
May, 2021

The impact of genetic risk on liver fibrosis in non-alcoholic fatty liver disease as assessed by magnetic resonance elastography.

Ajmera V, Liu A, Bettencourt R, Dhar D, Richards L, Loomba R. Aliment Pharmacol Ther. 2021 Jul;54(1):68-77. doi: 10.1111/apt.16392. Epub 2021 May 11.

View Publication
May, 2021

Influence of Psychological Biomarkers on Therapeutic Adherence by Patients with Non-Alcoholic Fatty Liver Disease: A Moderated Mediation Model.

Funuyet-Salas J, Martín-Rodríguez A, Pérez-San-Gregorio MÁ, Romero-Gómez M. J Clin Med. 2021 May 20;10(10):2208. doi: 10.3390/jcm10102208.

View Publication
May, 2021

The Burden of Nonalcoholic Fatty Liver Disease in Asia, Middle East and North Africa: Data from Global Burden of Disease 2009-2019.

Golabi P, Paik JM, AlQahtani S, Younossi Y, Tuncer G, Younossi ZM. J Hepatol. 2021 May 31:S0168-8278(21)00358-5. doi: 10.1016/j.jhep.2021.05.022.

View Publication
May, 2021

Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.

Mózes FE, Lee JA, Selvaraj EA, Jayaswal ANA, Trauner M, Boursier J, Fournier C, Staufer K, Stauber RE, Bugianesi E, Younes R, Gaia S, Lupșor-Platon M, Petta S, Shima T, Okanoue T, Mahadeva S, Chan WK, Eddowes PJ, Hirschfield GM, Newsome PN, Wong VW, de Ledinghen V, Fan J, Shen F, Cobbold JF, Sumida Y, Okajima A, Schattenberg JM, Labenz C, Kim W, Lee MS, Wiegand J, Karlas T, Yılmaz Y, Aithal GP, Palaniyappan N, Cassinotto C, Aggarwal S, Garg H, Ooi GJ, Nakajima A, Yoneda M, Ziol M, Barget N, Geier A, Tuthill T, Brosnan MJ, Anstee QM, Neubauer S, Harrison SA, Bossuyt PM, Pavlides M; LITMUS Investigators. Gut. 2021 May 17:gutjnl-2021-324243. doi: 10.1136/gutjnl-2021-324243.

View Publication
May, 2021

Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.

Caviglia GP, Armandi A, Rosso C, Gaia S, Aneli S, Rolle E, Abate ML, Olivero A, Nicolosi A, Guariglia M, Ribaldone DG, Carucci P, Saracco GM, Bugianesi E. Cancers (Basel). 2021 May 11;13(10):2305. doi: 10.3390/cancers13102305.

View Publication
May, 2021

Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis.

Selvaraj EA, Mózes FE, Ajmer Jayaswal AN, Zafarmand MH, Vali Y, Lee JA, Levick CK, Joseph Young LA, Palaniyappan N, Liu CH, Aithal GP, Romero-Gómez M, Brosnan MJ, Tuthill TA, Anstee QM, Neubauer S, Harrison SA, Bossuyt PM, Pavlides M; LITMUS Investigators. J Hepatol. 2021 May 12:S0168-8278(21)00309-3. doi: 10.1016/j.jhep.2021.04.044.

View Publication
May, 2021

Mechanisms and disease consequences of nonalcoholic fatty liver disease.

Loomba R, Friedman SL, Shulman GI. Cell. 2021 May 13;184(10):2537-2564. doi: 10.1016/j.cell.2021.04.015.

View Publication
May, 2021

Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis.

Albhaisi S, Sanyal AJ. Front Endocrinol (Lausanne). 2021 May 10;12:665987. doi: 10.3389/fendo.2021.665987.

View Publication
May, 2021

Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers.

Gil-Gómez A, Brescia P, Rescigno M, Romero-Gómez M. Semin Liver Dis. 2021 May;41(2):191-205. doi: 10.1055/s-0041-1723752.

View Publication
February, 2021

Implications of Abdominal Adipose Tissue Distribution on Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Chinese General Population Study.

Chiyanika C, Wong VW, Wong GL, Chan HL, Hui SCN, Yeung DKW, Chu WCW. Clin Transl Gastroenterol. 2021 Feb 17;12(2):e00300. doi: 10.14309/ctg.0000000000000300.

View Publication
February, 2021

Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease.

Alqahtani SA, Golabi P, Paik JM, Lam B, Moazez AH, Elariny HA, Goodman Z, Younossi ZM. Obes Surg. 2021 Feb 22. doi: 10.1007/s11695-020-04996-1.

View Publication
February, 2021

A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH.

Taylor-Weiner A, Pokkalla H, Han L, Jia C, Huss R, Chung C, Elliott H, Glass B, Pethia K, Carrasco-Zevallos O, Shukla C, Khettry U, Najarian R, Taliano R, Subramanian GM, Myers RP, Wapinski I, Khosla A, Resnick M, Montalto MC, Anstee QM, Wong VW, Trauner M, Lawitz EJ, Harrison SA, Okanoue T, Romero-Gomez M, Goodman Z, Loomba R, Beck AH, Younossi ZM. Hepatology. 2021 Feb 11. doi: 10.1002/hep.31750.

View Publication
February, 2021

Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in five european countries in 2018: A cost-of-illness analysis.

Schattenberg JM, Lazarus JV, Newsome PN, Serfaty L, Aghemo A, Augustin S, Tsochatzis E, de Ledinghen V, Bugianesi E, Romero-Gomez M, Bantel H, Ryder SD, Boursier J, Leroy V, Crespo J, Castera L, Floros L, Atella V, Mestre-Ferrandiz J, Elliott R, Kautz A, Morgan A, Hartmanis S, Vasudevan S, Pezzullo L, Trylesinski A, Cure S, Higgins V, Ratziu V. Liver Int. 2021 Feb 15. doi: 10.1111/liv.14825.

View Publication
February, 2021

Therapeutic pipeline in nonalcoholic steatohepatitis.

Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ. Nat Rev Gastroenterol Hepatol. 2021 Feb 10. doi: 10.1038/s41575-020-00408-y.

View Publication
February, 2021

Simple non-invasive scoring systems and histologic scores in predicting mortality in NAFLD patients: A systematic review and meta-analysis.

Liu CH, Ampuero J, Pavlides M, Wong VW, Fan JG, Bai L, Li H, Wu DB, Zhou LY, Du LY, Yang TK, Jiang W, Shi Y, Gil-Gómez A, Zhang WT, Liang JX, Romero-Gómez M, Tang H. J Gastroenterol Hepatol. 2021 Feb 10. doi: 10.1111/jgh.15431.

View Publication
February, 2021

Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?

Younes R, Govaere O, Petta S, Miele L, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, McLeod D, Pareja MJ, Fracanzani AL, Aller R, Rosso C, Ampuero J, Gallego-Durán R, Armandi A, Caviglia GP, Zaki MYW, Liguori A, Francione P, Pennisi G, Grieco A, Birolo G, Fariselli P, Eslam M, Valenti L, George J, Romero-Gómez M, Anstee QM, Bugianesi E. Gut. 2021 Feb 4:gutjnl-2020-322564. doi: 10.1136/gutjnl-2020-322564.

View Publication
February, 2021

Non-invasive Tests to Phenotype Nonalcoholic Fatty Liver Disease – Sequence and Consequences of Arranging the Tools In the Tool Box.

Vuppalanchi R, Loomba R. Hepatology. 2021 Feb 5. doi: 10.1002/hep.31734.

View Publication
February, 2021

Nonalcoholic Fatty Liver Disease and Cardiovascular Disease.

Przybyszewski EM, Targher G, Roden M, Corey KE. Clin Liver Dis (Hoboken). 2021 Feb 1;17(1):19-22. doi: 10.1002/cld.1017.

View Publication
February, 2021

Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: A population -based study.

Julián MT, Pera G, Soldevila B, Caballería L, Julve J, Puig-Jové C, Morillas R, Torán P, Expósito C, Puig-Domingo M, Castelblanco E, Franch-Nadal J, Cusi K, Mauricio D, Alonso N. Eur J Endocrinol. 2021 Feb 1:EJE-20-1240.R1. doi: 10.1530/EJE-20-1240.

View Publication
January, 2021

NAFLD-related HCC.

Banini BA, Sanyal AJ. Adv Cancer Res. 2021;149:143-169. doi: 10.1016/bs.acr.2020.11.001.

View Publication
January, 2021

Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.

Francque S, Szabo G, Abdelmalek MF, Byrne CD, Cusi K, Dufour JF, Roden M, Sacks F, Tacke F. Nat Rev Gastroenterol Hepatol. 2021 Jan;18(1):24-39. doi: 10.1038/s41575-020-00366-5.

View Publication
January, 2021

Weight Loss and Weight Regain in Usual Clinical Practice: Results from the TARGET-NASH Observational Cohort.

Malespin MH, Barritt AS 4th, Watkins SE, Schoen C, Tincopa MA, Corbin KD, Mospan AR, Munoz B, Trinh HN, Weiss LM, Reddy KR, Loomba R, Kemmer N, Lok AS.Clin Gastroenterol Hepatol. 2021 Jan 21:S1542-3565(21)00073-2. doi: 10.1016/j.cgh.2021.01.023.

View Publication
January, 2021

Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement.

Hagström H, Adams LA, Allen AM, Byrne CD, Chang Y, Grønbaek H, Ismail M, Jepsen P, Kanwal F, Kramer J, Lazarus JV, Long MT, Loomba R, Newsome PN, Rowe IA, Ryu S, Schattenberg JM, Serper M, Sheron N, Simon TG, Tapper EB, Wild S, Wong VW, Yilmaz Y, Zelber-Sagi S, Åberg F. Hepatology. 2021 Jan 23. doi: 10.1002/hep.31726.

View Publication
January, 2021

Fecal Microbiota Transplant from Human to Mice Gives Insights into the Role of the Gut Microbiota in Non-Alcoholic Fatty Liver Disease (NAFLD).

Burz SD, Monnoye M, Philippe C, Farin W, Ratziu V, Strozzi F, Paillarse JM, Chêne L, Blottière HM, Gérard P. Microorganisms. 2021 Jan 19;9(1):199. doi: 10.3390/microorganisms9010199.

View Publication
January, 2021

NAFLD as a metabolic disease in humans: A literature review.

Cariou B, Byrne CD, Loomba R, Sanyal AJ. Diabetes Obes Metab. 2021 Jan 19. doi: 10.1111/dom.14322.

View Publication
January, 2021

Relevance of fructose intake in adolescence for fatty liver indices in young adulthood.

Perrar I, Buyken AE, Penczynski KJ, Remer T, Kuhnle GG, Herder C, Roden M, Della Corte K, Nöthlings U, Alexy U. Eur J Nutr. 2021 Jan 19. doi: 10.1007/s00394-020-02463-2.

View Publication
January, 2021

Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis.

Petroff D, Blank V, Newsome PN, Shalimar, Voican CS, Thiele M, de Lédinghen V, Baumeler S, Chan WK, Perlemuter G, Cardoso AC, Aggarwal S, Sasso M, Eddowes PJ, Allison M, Tsochatzis E, Anstee QM, Sheridan D, Cobbold JF, Naveau S, Lupsor-Platon M, Mueller S, Krag A, Irles-Depe M, Semela D, Wong GL, Wong VW, Villela-Nogueira CA, Garg H, Chazouillères O, Wiegand J, Karlas T. Lancet Gastroenterol Hepatol. 2021 Jan 15:S2468-1253(20)30357-5. doi: 10.1016/S2468-1253(20)30357-5.

View Publication
January, 2021

Management of non-alcoholic fatty liver disease.

Petroni ML, Brodosi L, Bugianesi E, Marchesini G. BMJ. 2021 Jan 18;372:m4747. doi: 10.1136/bmj.m4747.

View Publication
January, 2021

Yet more evidence that MAFLD is more than name change.

Eslam M, Ratziu V, George J. J Hepatol. 2021 Jan 13:S0168-8278(21)00008-8. doi: 10.1016/j.jhep.2020.12.025.

View Publication
January, 2021

Imaging Biomarkers of NAFLD, NASH, and Fibrosis.

Ajmera V, Loomba R. Mol Metab. 2021 Jan 15:101167. doi: 10.1016/j.molmet.2021.101167.

View Publication
December, 2020

Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis.

Govaere O, Cockell S, Tiniakos D, Queen R, Younes R, Vacca M, Alexander L, Ravaioli F, Palmer J, Petta S, Boursier J, Rosso C, Johnson K, Wonders K, Day CP, Ekstedt M, Orešič M, Darlay R, Cordell HJ, Marra F, Vidal-Puig A, Bedossa P, Schattenberg JM, Clément K, Allison M, Bugianesi E, Ratziu V, Daly AK, Anstee QM. Sci Transl Med. 2020 Dec 2;12(572):eaba4448. doi: 10.1126/scitranslmed.aba4448.

View Publication
December, 2020

Cardiovascular risk in patients with nonalcoholic fatty liver disease: looking at the liver to shield the heart.

Cusi K, Godinez Leiva E. Curr Opin Lipidol. 2020 Dec;31(6):364-366. doi: 10.1097/MOL.0000000000000717.

View Publication
December, 2020

Identification of a metabolic, transcriptomic and molecular signature of PNPLA3-mediated acceleration of steatohepatitis.

Banini BA, P Kumar D, Cazanave S, Seneshaw M, Mirshahi F, Santhekadur PK, Wang L, Guan HP, Oseini A, Alonso C, Bedossa P, Koduru SV, Min HK, Sanyal AJ. Hepatology. 2020 Nov 1. doi: 10.1002/hep.31609.

View Publication
December, 2020

Role of ceramide-to-dihydroceramide ratios for insulin resistance and non-alcoholic fatty liver disease in humans.

Apostolopoulou M, Gordillo R, Gancheva S, Strassburger K, Herder C, Esposito I, Schlensak M, Scherer PE, Roden M. BMJ Open Diabetes Res Care. 2020 Nov;8(2):e001860. doi: 10.1136/bmjdrc-2020-001860.

View Publication
December, 2020

“The predictive value of significant fibrosis for metabolic disturbances in NAFLD patients”.

Ampuero J, Gallego-Durán R, Romero-Gómez M. J Hepatol. 2020 Dec 24:S0168-8278(20)33895-2. doi: 10.1016/j.jhep.2020.12.020.

View Publication
December, 2020

RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.

Afonso MB, Rodrigues PM, Mateus-Pinheiro M, Simão AL, Gaspar MM, Majdi A, Arretxe E, Alonso C, Santos A, Jimenez-Agüero R, Eizaguirre E, Bujanda L, Pareja MJ, Banales J, Ratziu V, Gautheron J, Castro RE, Rodrigues CM. Gut. 2020 Dec 24:gutjnl-2020-321767. doi: 10.1136/gutjnl-2020-321767.

View Publication
December, 2020

Liver stiffness by transient elastography to detect porto-sinusoidal vascular liver disease with portal hypertension.

Elkrief L, Lazareth M, Chevret S, Paradis V, Magaz M, Blaise L, Rubbia-Brandt L, Moga L, Durand F, Payancé A, Plessier A, Chaffaut C, Valla D, Malphettes M, Diaz A, Nault JC, Nahon P, Audureau E, Ratziu V, Castera L, Garcia Pagan JC, Ganne-Carrie N, Rautou PE; ANRS CO12 CirVir group.Hepatology. 2020 Dec 21. doi: 10.1002/hep.31688.

View Publication
December, 2020

Dihydroceramides in Triglyceride-Enriched VLDL Are Associated with Nonalcoholic Fatty Liver Disease Severity in Type 2 Diabetes.

Carlier A, Phan F, Szpigel A, Hajduch E, Salem JE, Gautheron J, Le Goff W, Guérin M, Lachkar F, Ratziu V, Hartemann A, Ferré P, Foufelle F, Bourron O. Cell Rep Med. 2020 Dec 22;1(9):100154. doi: 10.1016/j.xcrm.2020.100154.

View Publication
December, 2020

Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening.

Lomonaco R, Godinez Leiva E, Bril F, Shrestha S, Mansour L, Budd J, Portillo Romero J, Schmidt S, Chang KL, Samraj G, Malaty J, Huber K, Bedossa P, Kalavalapalli S, Marte J, Barb D, Poulton D, Fanous N, Cusi K. Diabetes Care. 2020 Dec 21:dc201997. doi: 10.2337/dc20-1997.

View Publication
December, 2020

Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.

Huang DQ, El-Serag HB, Loomba R. Nat Rev Gastroenterol Hepatol. 2020 Dec 21. doi: 10.1038/s41575-020-00381-6.

View Publication
December, 2020

Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease.

Kazankov K, Rosso C, Younes R, Armandi A, Hagström H, Møller HJ, Stål P, Bugianesi E, Grønbæk H. Front Med (Lausanne). 2020 Dec 18;7:616212. doi: 10.3389/fmed.2020.616212.

View Publication
December, 2020

Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study.

Doward LC, Balp MM, Twiss J, Slota C, Cryer D, Brass CA, Anstee QM, Sanyal AJ. Patient. 2020 Dec 18. doi: 10.1007/s40271-020-00485-w.

View Publication
December, 2020

Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain.

Romero-Gomez M, Kachru N, Zamorano MA, Darba J, Shreay S. Medicine (Baltimore). 2020 Dec 11;99(50):e23506. doi: 10.1097/MD.0000000000023506.

View Publication
December, 2020

Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease.

Bayoumi A, Jalil I, Metwally M, Adams LA, Aller R, García-Monzón C, Arias-Loste MT, Miele L, Petta S, Craxì A, Gallego-Durán R, Fischer J, Berg T, Qiao L, Liddle C, Bugianesi E, Romero-Gomez M, George J, Eslam M. PLoS One. 2020 Dec 11;15(12):e0243590. doi: 10.1371/journal.pone.0243590.

View Publication
December, 2020

AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review.

Younossi ZM, Corey KE, Lim JK. Gastroenterology. 2020 Dec 9:S0016-5085(20)35538-4. doi: 10.1053/j.gastro.2020.11.051.

View Publication
December, 2020

Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain.

Romero-Gomez M, Kachru N, Zamorano MA, Darba J, Shreay S. Medicine (Baltimore). 2020 Dec 11;99(50):e23506. doi: 10.1097/MD.0000000000023506.

View Publication
December, 2020

Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non-alcoholic fatty liver disease: results from two early phase randomized trials.

Beysen C, Schroeder P, Wu E, Brevard J, Ribadeneira M, Lu W, Dole K, O'Reilly TE, Morrow L, Hompesch M, Hellerstein MK, Li K, Johansson L, Kelly PF. Diabetes Obes Metab. 2020 Dec 2. doi: 10.1111/dom.14272.

View Publication
December, 2020

The Association of Histologic and Non-invasive Tests with Adverse Clinical and Patient-Reported Outcomes in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH).

Younossi ZM, Anstee QM, Wai-Sun Wong V, Trauner M, Lawitz EJ, Harrison SA, Camargo M, Kersey K, Subramanian GM, Myers RP, Stepanova M. Gastroenterology. 2020 Dec 8:S0016-5085(20)35529-3. doi: 10.1053/j.gastro.2020.12.003.

View Publication
December, 2020

Non-alcoholic fatty liver disease: Not time for an obituary just yet!

Singh SP, Anirvan P, Reddy KR, Conjeevaram HS, Marchesini G, Rinella ME, Madan K, Petroni ML, Al-Mahtab M, Caldwell SH, Aithal GP, Hamid SS, Farrell GC, Satapathy SK, Duseja A, Acharya SK, Dassanayake AS, Goh KL. J Hepatol. 2020 Dec 16:S0168-8278(20)33729-6. doi: 10.1016/j.jhep.2020.10.015.

View Publication
December, 2020

Association between gut permeability and insulin resistance: Any role for zonulin in patients with non-alcoholic fatty liver disease?

Singh SP, Anirvan P, Reddy KR, Conjeevaram HS, Marchesini G, Rinella ME, Madan K, Petroni ML, Al-Mahtab M, Caldwell SH, Aithal GP, Hamid SS, Farrell GC, Satapathy SK, Duseja A, Acharya SK, Dassanayake AS, Goh KL. J Hepatol. 2020 Dec 16:S0168-8278(20)33729-6. doi: 10.1016/j.jhep.2020.10.015.

View Publication
November, 2020

Sex Hormone Relations to Histologic Severity of Pediatric Nonalcoholic Fatty Liver Disease.

Mueller NT, Liu T, Mitchel EB, Yates KP, Suzuki A, Behling C, Lavine JE. J Clin Endocrinol Metab. 2020 Nov 1;105(11):dgaa574. doi: 10.1210/clinem/dgaa574.

View Publication
November, 2020

A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients.

Eslam M, Wong GL, Hashem AM, Chan HL, Nielsen MJ, Leeming DJ, Chan AW, Chen Y, Duffin KL, Karsdal M, Schattenberg JM, George J, Wong VW. Am J Gastroenterol. 2020 Nov 26. doi: 10.14309/ajg.0000000000001059.

View Publication
November, 2020

Early changes in hepatic energy metabolism and lipid content in recent-onset type 1 and 2 diabetes mellitus.

Kupriyanova Y, Zaharia OP, Bobrov P, Karusheva Y, Burkart V, Szendroedi J, Hwang JH, Roden M; GDS group. J Hepatol. 2020 Nov 28:S0168-8278(20)33817-4. doi: 10.1016/j.jhep.2020.11.030.

View Publication
November, 2020

Overall clinical and economic impact of non-alcoholic fatty liver disease.

Sicras-Mainar A, Aller R, Crespo J, Calleja JL, Turnes J, Romero-Gómez M, Augustín S. Rev Esp Enferm Dig. 2020 Nov 23. doi: 10.17235/reed.2020.7238/2020.

View Publication
November, 2020

Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.

Bianco C, Jamialahmadi O, Pelusi S, Baselli G, Dongiovanni P, Zanoni I, Santoro L, Maier S, Liguori A, Meroni M, Borroni V, D'Ambrosio R, Spagnuolo R, Alisi A, Federico A, Bugianesi E, Petta S, Miele L, Vespasiani-Gentilucci U, Anstee QM, Stickel F, Hampe J, Fischer J, Berg T, Fracanzani AL, Soardo G, Reeves H, Prati D, Romeo S, Valenti L.J Hepatol. 2020 Nov 25:S0168-8278(20)33811-3. doi: 10.1016/j.jhep.2020.11.024.

View Publication
November, 2020

MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis.

Jung J,Loomba RR, Imajo K, Madamba E, Gandhi S, Bettencourt R, Singh S, Hernandez C, Valasek MA, Behling C, Richards L, Fowler K, Sirlin CB, Nakajima A, Loomba R. Gut. 2020 Nov 19:gutjnl-2020-322976. doi: 10.1136/gutjnl-2020-322976.

View Publication
November, 2020

Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P.

Caviglia GP, Rosso C, Armandi A, Gaggini M, Carli F, Abate ML, Olivero A, Ribaldone DG, Saracco GM, Gastaldelli A, Bugianesi E. Int J Mol Sci. 2020 Nov 22;21(22):E8838. doi: 10.3390/ijms21228838.

View Publication
November, 2020

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.

Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal AJ, Sejling AS, Harrison SA; NN9931-4296 Investigators. N Engl J Med. 2020 Nov 13. doi: 10.1056/NEJMoa2028395.

View Publication
November, 2020

Non-alcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans.

Pafili K, Roden M. Mol Metab. 2020 Nov 18:101122. doi: 10.1016/j.molmet.2020.101122.

View Publication
November, 2020

MRI-PDFF treatment response criteria in nonalcoholic steatohepatitis.

Loomba R. Hepatology. 2020 Nov 11. doi: 10.1002/hep.31624.

View Publication
November, 2020

Progression of Fatty Liver Disease in Children Receiving Standard of Care Lifestyle Advice.

Xanthakos SA, Lavine JE, Yates KP, Schwimmer JB, Molleston JP, Rosenthal P, Murray KF, Vos MB, Jain AK, Scheimann AO, Miloh T, Fishbein M, Behling CA, Brunt EM, Sanyal AJ, Tonascia J; NASH Clinical Research Network. Gastroenterology. 2020 Nov;159(5):1731-1751.e10. doi: 10.1053/j.gastro.2020.07.034.

View Publication
November, 2020

Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis due to NASH.

Loomba R, Noureddin M, Kowdley KV, Kohli A, Sheikh A, Neff G, Bhandari BR, Gunn N, Caldwell SH, Goodman Z, Wapinski I, Resnick M, Beck AH, Ding D, Jia C, Chuang JC, Huss RS, Chung C, Subramanian GM, Myers RP, Patel K, Borg BB, Ghalib R, Kabler H, Poulos J, Younes Z, Elkhashab M, Hassanein T, Iyer R, Ruane P, Shiffman ML, Strasser S, Wong VW, Alkhouri N; ATLAS Investigators. Hepatology. 2020 Nov 10. doi: 10.1002/hep.31622.

View Publication
November, 2020

Clinical utility of change in nonalcoholic fatty liver disease activity score and change in fibrosis in NAFLD.

Tamaki N, Munaganuru N, Jung J, Yonan AQ, Bettencourt R, Ajmera V, Valasek MA, Behling C, Loomba R. Clin Gastroenterol Hepatol. 2020 Nov 3:S1542-3565(20)31518-4. doi: 10.1016/j.cgh.2020.11.005.

View Publication
November, 2020

A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients with Nonalcoholic Steatohepatitis.

Siddiqui MS, Idowu MO, Parmar D, Borg BB, Denham D, Loo NM, Lazas D, Younes Z, Sanyal AJ. Clin Gastroenterol Hepatol. 2020 Nov 2:S1542-3565(20)31509-3. doi: 10.1016/j.cgh.2020.10.051.

View Publication
October, 2020

The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease.

Hardy T, Wonders K, Younes R, Aithal GP, Aller R, Allison M, Bedossa P, Betsou F, Boursier J, Brosnan MJ, Burt A, Cobbold J, Cortez-Pinto H, Day CP, Dufour JF, Ekstedt M, Francque S, Harrison S, Miele L, Nasr P, Papatheodoridis G, Petta S, Tiniakos D, Torstenson R, Valenti L, Holleboom AG, Yki-Jarvinen H, Geier A, Romero-Gomez M, Ratziu V, Bugianesi E, Schattenberg JM, Anstee QM; LITMUS Consortium. Contemp Clin Trials. 2020 Oct 9;98:106175. doi: 10.1016/j.cct.2020.106175.

View Publication
October, 2020

3D analysis of microvasculature in murine liver fibrosis models using synchrotron radiation-based microtomography.

Wagner WL, Föhst S, Hock J, Kim YO, Popov Y, Schuppan D, Schladitz K, Redenbach C, Ackermann M. Angiogenesis. 2020 Oct 10. doi: 10.1007/s10456-020-09751-9.

View Publication
October, 2020

Expert Panel Review on Non-Alcoholic Fatty Liver Disease in Persons with HIV.

Lake JE, Overton T, Naggie S, Sulkowski M, Loomba R, Kleiner DE, Price JC, Chew KW, Chung RT, Corey KE. Clin Gastroenterol Hepatol. 2020 Oct 15:S1542-3565(20)31431-2. doi: 10.1016/j.cgh.2020.10.018.

View Publication
October, 2020

Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers.

Harrison SA, Calanna S, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal A, Sejling AS, Newsome PN. Contemp Clin Trials. 2020 Oct 8:106174. doi: 10.1016/j.cct.2020.106174.

View Publication
October, 2020

Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease.

Arab JP, Dirchwolf M, Álvares-da-Silva MR, Barrera F, Benítez C, Castellanos-Fernandez M, Castro-Narro G, Chavez-Tapia N, Chiodi D, Cotrim H, Cusi K, de Oliveira CPMS, Díaz J, Fassio E, Gerona S, Girala M, Hernandez N, Marciano S, Masson W, Mendez-Sanchez N, Leite N, Lozano A, Padilla M, Panduro A, Paraná R, Parise E, Perez M, Poniachik J, Restrepo JC, Ruf A, Silva M, Tagle M, Tapias M, Torres K, Vilar-Gomez E, Costa Gil JE, Gadano A, Arrese M. Ann Hepatol. 2020 Oct 5:S1665-2681(20)30177-0. doi: 10.1016/j.aohep.2020.09.006.

View Publication
October, 2020

In vivo absolute quantification of hepatic γ-ATP concentration in mice using 31 P MRS at 11.7 T.

Rothe M, Wessel C, Cames S, Szendroedi J, Burkart V, Hwang JH, Roden M. NMR Biomed. 2020 Oct 6:e4422. doi: 10.1002/nbm.4422.

View Publication
October, 2020

The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. Hepatol Int. 2020 Oct 1. doi: 10.1007/s12072-020-10094-2.

View Publication
October, 2020

Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.

Budd J, Cusi K. Curr Diab Rep. 2020 Oct 5;20(11):59. doi: 10.1007/s11892-020-01349-1.

View Publication
September, 2020

ABIDE: an accurate predictive model of liver decompensation in patients with non-alcoholic fatty liver-related cirrhosis.

Calzadilla-Bertot L, Vilar-Gomez E, Wong VW, Romero-Gomez M, Aller-de la Fuente R, Wong GL, Castellanos M, Eslam M, Desai AP, Jeffrey GP, George J, Chalasani N, Adams LA. Hepatology. 2020 Sep 25. doi: 10.1002/hep.31576.

View Publication
September, 2020

Optimal Threshold of Controlled Attenuation Parameter for Detection of HIV-Associated NAFLD With Magnetic Resonance Imaging as the Reference Standard.

Ajmera VH, Cachay ER, Ramers CB, Bassirian S, Singh S, Bettencourt R, Richards L, Hamilton G, Middleton M, Fowler K, Sirlin C, Loomba R. Clin Infect Dis. 2020 Sep 25:ciaa429. doi: 10.1093/cid/ciaa429.

View Publication
September, 2020

Association Between Lipoprotein Particles and Atherosclerotic Events in Nonalcoholic Fatty Liver Disease.

Patel S, Siddiqui MB, Roman JH, Zhang E, Lee E, Shen S, Faridnia M, Mintini RJ, Boyett S, Idowu MO, Sanyal AJ, Luketic VA, Siddiqui MS. Clin Gastroenterol Hepatol. 2020 Sep 29:S1542-3565(20)31369-0. doi: 10.1016/j.cgh.2020.09.039.

View Publication
September, 2020

The times they are a-changin’ (for NAFLD as well).

Ratziu V, Rinella M, Beuers U, Loomba R, Anstee QM, Harrison S, Francque S, Sanyal A, Newsome PN, Younossi Z. J Hepatol. 2020 Sep 2:S0168-8278(20)33599-6. doi: 10.1016/j.jhep.2020.08.028.

View Publication
September, 2020

Dietary Rapeseed Oil Supplementation Reduces Hepatic Steatosis in Obese Men – A Randomized Controlled Trial.

Kruse M, Kemper M, Gancheva S, Osterhoff M, Dannenberger D, Markgraf D, Machann J, Hierholzer J, Roden M, Pfeiffer AFH. Mol Nutr Food Res. 2020 Sep 13:e2000419. doi: 10.1002/mnfr.202000419.

View Publication
September, 2020

Clinical endpoints are necessary in the interim analysis of REGENERATE – Authors’ reply.

Ratziu V, Younossi ZM, Campagna JA, MacConell L, Sanyal AJ. Lancet. 2020 Sep 5;396(10252):663-664. doi: 10.1016/S0140-6736(20)30807-2.

View Publication
September, 2020

A New, Non-Invasive Scale for Steatosis Developed Using Real-World Data From Russian Outpatients to Aid in the Diagnosis of Non-Alcoholic Fatty Liver Disease.

Maev IV, Samsonov AA, Lazebnik LB, Golovanova EV, Pavlov CS, Vovk EI, Ratziu V, Starostin KM. Adv Ther. 2020 Sep 16. doi: 10.1007/s12325-020-01493-w.

View Publication
September, 2020

CPAP Did Not Improve Nonalcoholic Fatty Liver Disease in Patients with Obstructive Sleep Apnea: A Randomized Clinical Trial.

Ng SS, Wong VW, Wong GL, Chu WC, Chan TO, To KW, Ko FW, Chan KP, Hui DS. Am J Respir Crit Care Med. 2020 Sep 14. doi: 10.1164/rccm.202005-1868OC.

View Publication
September, 2020

Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts.

Calleja-Panero JL, Andrade RJ, Bañares R, Crespo J, Esteban R, Jarque I, Mingot-Castellano ME, Romero-Gómez M, Muñoz-Peñín R, Bentley R, Shepherd J, Gil Aguirre A. Rev Esp Enferm Dig. 2020 Sep 21;112. doi: 10.17235/reed.2020.6895/2020.

View Publication
August, 2020

Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices.

Younossi ZM, Corey KE, Alkhouri N, Noureddin M, Jacobson I, Lam B, Clement S, Basu R, Gordon SC, Ravendhra N, Puri P, Rinella M, Scudera P, Singal AK, Henry L; US Members of the Global Nash Council. Aliment Pharmacol Ther. 2020 Aug;52(3):513-526. doi: 10.1111/apt.15830. Epub 2020 Jun 29.PMID: 32598051

View Publication
July, 2020

From NAFLD to MAFLD: a “redefining” moment for fatty liver disease.

Zheng KI, Fan JG, Shi JP, Wong VW, Eslam M, George J, Zheng MH. Chin Med J (Engl). 2020 Jul 21. doi: 10.1097/CM9.0000000000000981. Online ahead of print.PMID: 32701591 

View Publication
July, 2020

Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH.

Hydes TJ, Ravi S, Loomba R, E Gray M. Clin Mol Hepatol. 2020 Jul 17. doi: 10.3350/cmh.2020.0067. Online ahead of print.PMID: 32674529 

View Publication
July, 2020

Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice.

Perdomo C, D'Ingianna P, Escalada J, Petta S, Romero Gómez M, Ampuero J. Pol Arch Intern Med. 2020 Jul 14. doi: 10.20452/pamw.15510. Online ahead of print.PMID: 32666779

View Publication
July, 2020

Physical Activity, Measured Objectively, is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease.

Kim D, Murag S, Cholankeril G, Cheung A, Harrison SA, Younossi ZM, Ahmed A. Clin Gastroenterol Hepatol. 2020 Jul 16:S1542-3565(20)30985-X. doi: 10.1016/j.cgh.2020.07.023. Online ahead of print.PMID: 32683103

View Publication
July, 2020

Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.

Patel K, Harrison SA, Elkhashab M, Trotter JF, Herring R, Rojter SE, Kayali Z, Wong VW, Greenbloom S, Jayakumar S, Shiffman ML, Freilich B, Lawitz EJ, Gane EJ, Harting E, Xu J, Billin AN, Chung C, Djedjos CS, Subramanian GM, Myers RP, Middleton MS, Rinella M, Noureddin M. Hepatology. 2020 Jul;72(1):58-71. doi: 10.1002/hep.31205.PMID: 32115759

View Publication
July, 2020

MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study.

Han MAT, Vipani A, Noureddin N, Ramirez K, Gornbein J, Saouaf R, Baniesh N, Cummings-John O, Okubote T, Setiawan VW, Rotman Y, Loomba R, Alkhouri N, Noureddin M. Liver Int. 2020 Jul 11. doi: 10.1111/liv.14593. Online ahead of print.PMID: 32652744

View Publication
July, 2020

The PREDICT study uncovers three clinical courses in acutely decompensated cirrhosis with distinct pathophysiology.

Trebicka J, Fernandez J, Papp M, Caraceni P, Laleman W, Gambino C, Giovo I, Uschner FE, Jimenez C, Mookerjee R, Gustot T, Albillos A, Bañares R, Janicko M, Steib C, Reiberger T, Acevedo J, Gatti P, Bernal W, Zeuzem S, Zipprich A, Piano S, Berg T, Bruns T, Bendtsen F, Coenraad M, Merli M, Stauber R, Zoller H, Ramos JP, Solé C, Soriano G, de Gottardi A, Gronbaek H, Saliba F, Trautwein C, Özdogan OC, Francque S, Ryder S, Nahon P, Romero-Gomez M, Van Vlierberghe H, Francoz C, Manns M, Garcia E, Tufoni M, Amoros A, Pavesi M, Sanchez C, Curto A, Pitarch C, Putignano A, Moreno E, Shawcross D, Aguilar F, Claria J, Ponzo P, Jansen C, Vitalis Z, Zaccherini G, Balogh B, Vargas V, Montagnese S, Alessandria C, Bernardi M, Ginès P, Jalan R, Moreau R, Angeli P, Arroyo V; PREDICT STUDY group of the EASL-CLIF CONSORTIUM. J Hepatol. 2020 Jul 13:S0168-8278(20)30384-6. doi: 10.1016/j.jhep.2020.06.013. Online ahead of print.PMID: 32673741 

View Publication
July, 2020

Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH.

Ampuero J, Aller R, Gallego-Durán R, Crespo J, Calleja JL, García-Monzón C, Gómez-Camarero J, Caballería J, Lo Iacono O, Ibañez L, García-Samaniego J, Albillos A, Francés R, Fernández-Rodríguez C, Diago M, Soriano G, Andrade RJ, Latorre R, Jorquera F, Morillas RM, Escudero D, Estévez P, Hernandez-Guerra M, Augustín S, Bañales J, Aspichueta P, Benlloch S, Rosales JM, Salmerón J, Turnes J, Romero-Gómez M; HEPAmet Registry. J Hepatol. 2020 Jul;73(1):17-25. doi: 10.1016/j.jhep.2020.02.028.

View Publication
July, 2020

Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease.

Lang S, Demir M, Martin A, Jiang L, Zhang X, Duan Y, Gao B, Wisplinghoff H, Kasper P, Roderburg C, Tacke F, Steffen HM, Goeser T, Abraldes JG, Tu XM, Loomba R, Stärkel P, Pride D, Fouts DE, Schnabl B. Gastroenterology. 2020 Jul 8:S0016-5085(20)34923-4. doi: 10.1053/j.gastro.2020.07.005. Online ahead of print.PMID: 32652145

View Publication
July, 2020

Review article: The impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis.

Connelly MA, Velez Rivera J, Guyton JR, Siddiqui MS, Sanyal AJ. Aliment Pharmacol Ther. 2020 Jul 8. doi: 10.1111/apt.15935. Online ahead of print.PMID: 32638417 

View Publication
July, 2020

Real-World Burden of Nonalcoholic Steatohepatitis.

Geier A, Rinella M, Balp MM, McKenna SJ, Brass C, Przybysz R, Cai J, Knight A, Gavaghan M, Howe T, Rosen D, Ratziu V. Clin Gastroenterol Hepatol. 2020 Jul 4:S1542-3565(20)30928-9. doi: 10.1016/j.cgh.2020.06.064. Online ahead of print.PMID: 32634622

View Publication
July, 2020

Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.

Yamamura S, Nakano D, Hashida R, Tsutsumi T, Kawaguchi T, Okada M, Isoda H, Takahashi H, Matsuse H, Eguchi Y, Sumida Y, Nakajima A, Gerber L, Younossi ZM, Torimura T. J Gastroenterol Hepatol. 2020 Jul 6. doi: 10.1111/jgh.15172. Online ahead of print.PMID: 32627871 

View Publication
July, 2020

Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver disease.

Petta S, Sebastiani G, Viganò M, Ampuero J, Wai-Sun Wong V, Boursier J, Berzigotti A, Bugianesi E, Fracanzani AL, Cammà C, Enea M, Grottes MD, Di Marco V, Younes R, Keyrouz A, Mazzola S, Mendoza Y, Pennisi G, Romero-Gomez M, Craxì A, de Ledinghen V. Clin Gastroenterol Hepatol. 2020 Jul 1:S1542-3565(20)30908-3. doi: 10.1016/j.cgh.2020.06.045. Online ahead of print.PMID: 32621970

View Publication
July, 2020

Important Unresolved Questions in the Management of Hepatic Encephalopathy: An ISHEN Consensus.

Bajaj JS, Lauridsen M, Tapper EB, Duarte-Rojo A, Rahimi RS, Tandon P, Shawcross DL, Thabut D, Dhiman RK, Romero-Gomez M, Sharma BC, Montagnese S. Am J Gastroenterol. 2020 Jul;115(7):989-1002. doi: 10.14309/ajg.0000000000000603.PMID: 32618647

View Publication
June, 2020

What Has the COVID-19 Pandemic Taught Us so Far? Addressing the Problem from a Hepatologist’s Perspective.

Méndez-Sánchez N, Valencia-Rodríguez A, Qi X, Yoshida EM, Romero-Gómez M, George J, Eslam M, Abenavoli L, Xie W, Teschke R, Carrion AF, Keaveny AP.
J Clin Transl Hepatol. 2020 Jun 28;8(2):0024. doi: 10.14218/JCTH.2020.00024. Epub 2020 Apr 11.

View Publication
June, 2020

Mitochondrial oxidative injury: A key player in nonalcoholic fatty liver disease.

Dornas W, Schuppan D. Am J Physiol Gastrointest Liver Physiol. 2020 Jun 29. doi: 10.1152/ajpgi.00121.2020. Online ahead of print.PMID: 32597705

View Publication
June, 2020

A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis.

Oh TG, Kim SM, Caussy C, Fu T, Guo J, Bassirian S, Singh S, Madamba EV, Bettencourt R, Richards L, Raffatellu M, Dorrestein PC, Yu RT, Atkins AR, Huan T, Brenner DA, Sirlin CB, Knight R, Downes M, Evans RM, Loomba R. Cell Metab. 2020 Jun 30:S1550-4131(20)30306-5. doi: 10.1016/j.cmet.2020.06.005. Online ahead of print.PMID: 32610095

View Publication
June, 2020

Metabolic liver disease in diabetes – From mechanisms to clinical trials.

Dewidar B, Kahl S, Pafili K, Roden M. Metabolism. 2020 Jun 20:154299. doi: 10.1016/j.metabol.2020.154299. Online ahead of print.PMID: 32569680 

View Publication
June, 2020

Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.

Loomba R, Morgan E, Watts L, Xia S, Hannan LA, Geary RS, Baker BF, Bhanot S. Lancet Gastroenterol Hepatol. 2020 Jun 15:S2468-1253(20)30186-2. doi: 10.1016/S2468-1253(20)30186-2. Online ahead of print.PMID: 32553151

View Publication
June, 2020

From NAFLD to MAFLD: Implications of a premature change in terminology.

Younossi ZM, Rinella ME, Sanyal A, Harrison SA, Brunt E, Goodman Z, Cohen DE, Loomba R. Hepatology. 2020 Jun 16. doi: 10.1002/hep.31420. Online ahead of print.PMID: 32544255

View Publication
June, 2020

Bacterial antigen translocation and age as BMI-independent contributing factors on systemic inflammation in NAFLD patients.

Gómez-Hurtado I, Gallego-Durán R, Zapater P, Ampuero J, Aller R, Crespo J, Arias-Loste M, García-Monzón C, Bellot P, González-Rodríguez Á, Juanola O, Romero-Gómez M, Francés R. Liver Int. 2020 Jun 19. doi: 10.1111/liv.14571. Online ahead of print.PMID: 32559006

View Publication
June, 2020

Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: Data from Hong Kong.

Tampi RP, Wong VW, Wong GL, Shu SS, Chan HL, Fung J, Stepanova M, Younossi ZM. Hepatol Res. 2020 Jun 14. doi: 10.1111/hepr.13535. Online ahead of print.PMID: 32537840

View Publication
May, 2020

A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.

Harrison SA, Goodman Z, Jabbar A, Vemulapalli R, Younes ZH, Freilich B, Sheikh MY, Schattenberg JM, Kayali Z, Zivony A, Sheikh A, Garcia-Samaniego J, Satapathy SK, Therapondos G, Mena E, Schuppan D, Robinson J, Chan JL, Hagerty DT, Sanyal AJ.
J Hepatol. 2020 May;72(5):816-827. doi: 10.1016/j.jhep.2019.11.024. Epub 2019 Dec 27. 

View Publication
April, 2020

Characterization of the variability in the extent of nonalcoholic fatty liver induced by a high-fat diet in the genetically diverse Collaborative Cross mouse model.

de Conti A, Tryndyak V, Willett RA, Borowa-Mazgaj B, Watson A, Patton R, Khare S, Muskhelishvili L, Olson GR, Avigan MI, Cerniglia CE, Ross SA, Sanyal AJ, Beland FA, Rusyn I, Pogribny IP.
FASEB J. 2020 Apr 18. doi: 10.1096/fj.202000194R.

View Publication
April, 2020

Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population.

Sayiner M, Arshad T, Golabi P, Paik J, Farhat F, Younossi ZM.
Hepatol Int. 2020 Apr 16. doi: 10.1007/s12072-020-10038-w.

View Publication
April, 2020

Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement.

Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, Pratt DS, Russo MW, Schilsky ML, Verna EC, Loomba R, Cohen DE, Bezerra JA, Reddy KR, Chung RT.
Hepatology. 2020 Apr 16. doi: 10.1002/hep.31281.

View Publication
April, 2020

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.

Hartman ML, Sanyal AJ, Loomba R, Wilson JM, Nikooienejad A, Bray R, Karanikas CA, Duffin KL, Robins DA, Haupt A.
Diabetes Care. 2020 Apr 14. pii: dc191892. doi: 10.2337/dc19-1892.

View Publication
April, 2020

Have incidence rates of liver cancer peaked in the United States?

Petrick JL, Florio AA, Loomba R, McGlynn KA.
Cancer. 2020 Apr 15. doi: 10.1002/cncr.32794.

View Publication
April, 2020

Longitudinal relationship of amino acids and indole metabolites with long-term body mass index and cardiometabolic risk markers in young individuals.

Oluwagbemigun K, Anesi A, Ulaszewska M, Clarke G, Alexy U, Schmid M, Roden M, Herder C, Mattivi F, Nöthlings U.
Sci Rep. 2020 Apr 14;10(1):6399. doi: 10.1038/s41598-020-63313-z.

View Publication
April, 2020

Impact of osteopontin on the development of non-alcoholic liver disease and related hepatocellular carcinoma.

Nardo AD, Grün NG, Zeyda M, Dumanic M, Oberhuber G, Rivelles E, Helbich TH, Markgraf DF, Roden M, Claudel T, Trauner M, Stulnig TM.
Liver Int. 2020 Apr 13. doi: 10.1111/liv.14464.

View Publication
April, 2020

A new definition for metabolic associated fatty liver disease: an international expert consensus statement.

Eslam M, Newsome PN, Anstee QM, Targher G, Gomez MR, Zelber-Sagi S, Wong VW, Dufour JF, Schattenberg J, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Järvinen H, Fan JG, Gronbaek H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J.
J Hepatol. 2020 Apr 8. pii: S0168-8278(20)30201-4. doi: 10.1016/j.jhep.2020.03.039.

View Publication
April, 2020

Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically-characterised cohort.

Anstee QM, Darlay R, Cockell S, Meroni M, Govaere O, Tiniakos D, Burt AD, Bedossa P, Palmer J, Liu YL, Aithal GP, Allison M, Yki-Järvinen H, Vacca M, Dufour JF, Invernizzi P, Prati D, Ekstedt M, Kechagias S, Francque S, Petta S, Bugianesi E, Clement K, Ratziu V, Schattenberg JM, Valenti L, Day CP, Cordell HJ, Daly AK; EPoS Consortium Investigators.
J Hepatol. 2020 Apr 13. pii: S0168-8278(20)30213-0. doi: 10.1016/j.jhep.2020.04.003.

View Publication
April, 2020

Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis.

Vali Y, Lee J, Boursier J, Spijker R, Löffler J, Verheij J, Brosnan MJ, Böcskei Z, Anstee QM, Bossuyt PM, Zafarmand MH; LITMUS systematic review team, Pavlides M, Levick C, Duffin K, Hyde C, Bauer T, Bedossa P, Leeming D, Daly A, Hanf R, Ortiz P, Oresic M, Schuppan D, Hanauer G, Chen Y, Shumbayawonda E, Bjerring PN, Zwinderman K.
J Hepatol. 2020 Apr 7. pii: S0168-8278(20)30198-7. doi: 10.1016/j.jhep.2020.03.036.

View Publication
April, 2020

Timing Is Everything: Improving NASH Histology in Clinical Trials Should Not Be Rushed.

Ratziu V.
Hepatology. 2020 Apr;71(4):1146-1149. doi: 10.1002/hep.31213.

View Publication
April, 2020

Modelling NAFLD disease burden in four Asian regions-2019-2030.

Estes C, Chan HLY, Chien RN, Chuang WL, Fung J, Goh GB, Hu TH, Huang JF, Jang BK, Jun DW, Kao JH, Lee JW, Lin HC, Razavi-Shearer K, Seto WK, Wong GL, Wong VW, Razavi H.
Aliment Pharmacol Ther. 2020 Apr;51(8):801-811. doi: 10.1111/apt.15673.

View Publication
April, 2020

Increased Release of Proinflammatory Proteins in Primary Human Adipocytes and Activation of the Inflammatory NFĸB, p38, and ERK Pathways upon Omentin Treatment.

Niersmann C, Röhrig K, Blüher M, Roden M, Herder C, Carstensen-Kirberg M.
Obes Facts. 2020 Apr 6:1-16. doi: 10.1159/000506405.

View Publication
April, 2020

Collagen biology and non-invasive biomarkers of liver fibrosis.

Karsdal MA, Daniels SJ, Holm Nielsen S, Bager C, Rasmussen DGK, Loomba R, Surabattula R, Villesen IF, Luo Y, Shevell D, Gudmann NS, Nielsen MJ, George J, Christian R, Leeming DJ, Schuppan D.
Liver Int. 2020 Apr;40(4):736-750. doi: 10.1111/liv.14390.

View Publication
April, 2020

Circulating extracellular vesicles carrying sphingolipid cargo for the diagnosis and dynamic risk profiling of alcoholic hepatitis.

Sehrawat TS, Arab JP, Liu M, Amrollahi P, Wan M, Fan J, Nakao Y, Pose E, Navarro-Corcuera A, Dasgupta D, Liao CY, He L, Mauer AS, Avitabile E, Ventura-Cots M, Bataller RA, Sanyal AJ, Chalasani NP, Heimbach JK, Watt KD, Gores GJ, Gines P, Kamath PS, Simonetto DA, Hu TY, Shah VH, Malhi H.
Hepatology. 2020 Apr 4. doi: 10.1002/hep.31256.

View Publication
April, 2020

Circulating Zonulin is Related to Hepatic Necroinflammation in Patients with Non Alcoholic Fatty Liver Disease.

Rosso C, Caviglia GP, Younes R, Foglia B, Blanco MJG, Ribaldone DG, Bugianesi E.
Clin Lab. 2020 Apr 1;66(4). doi: 10.7754/Clin.Lab.2019.190922.

View Publication
April, 2020

Outcomes of liver transplantation by insurance types in the United States.

Stepanova M, Al Qahtani S, Mishra A, Younossi I, Venkatesan C, Younossi ZM.
Am J Manag Care. 2020 Apr 1;26(4):e121-e126. doi: 10.37765/ajmc.2020.42839.
PMID: 32270989

View Publication
March, 2020

Relationship between non-alcoholic fatty liver disease during pregnancy and abnormal glucose metabolism during and after pregnancy.

Sattari M, Bril F, Egerman R, Kalavalapalli S, Cusi K.
J Investig Med. 2020 Mar;68(3):743-747. doi: 10.1136/jim-2019-001186. Epub 2019 Dec 17.

View Publication
March, 2020

Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges.

Goldner D, Lavine JE.
Gastroenterology. 2020 Mar 20. pii: S0016-5085(20)30168-2. doi: 10.1053/j.gastro.2020.01.048.

View Publication
March, 2020

Lysyl oxidase (LOX) family members: rationale and their potential as therapeutic targets for liver fibrosis.

Chen W, Yang A, Jia J, Popov YV, Schuppan D, You H.
Hepatology. 2020 Mar 16. doi: 10.1002/hep.31236. [Epub ahead of print] Review.
PMID: 32176358

View Publication
February, 2020

Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat with Radiofrequency Ultrasound Data Using One-dimensional Convolutional Neural Networks.

Han A, Byra M, Heba E, Andre MP, Erdman JW Jr, Loomba R, Sirlin CB, O'Brien WD Jr.
Radiology. 2020 Feb 25:191160. doi: 10.1148/radiol.2020191160.

View Publication
February, 2020

Longitudinal Association of Non-Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study.

VanWagner LB, Wilcox JE, Ning H, Lewis CE, Carr JJ, Rinella ME, Shah SJ, Lima JAC, Lloyd-Jones DM.
J Am Heart Assoc. 2020 Feb 18;9(4):e014279. doi: 10.1161/JAHA.119.014279.

View Publication
February, 2020

Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly.

Simon J, Nuñez-García M, Fernández-Tussy P, Barbier-Torres L, Fernández-Ramos D, Gómez-Santos B, Buqué X, Lopitz-Otsoa F, Goikoetxea-Usandizaga N, Serrano-Macia M, Rodriguez-Agudo R, Bizkarguenaga M, Zubiete-Franco I, Gutiérrez-de Juan V, Cabrera D, Alonso C, Iruzubieta P, Romero-Gomez M, van Liempd S, Castro A, Nogueiras R, Varela-Rey M, Falcón-Pérez JM, Villa E, Crespo J, Lu SC, Mato JM, Aspichueta P, Delgado TC, Martínez-Chantar ML.
Cell Metab. 2020 Feb 20. pii: S1550-4131(20)30056-5. doi: 10.1016/j.cmet.2020.01.013.

View Publication
February, 2020

Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease.

Musolino V, Gliozzi M, Scarano F, Bosco F, Scicchitano M, Nucera S, Carresi C, Ruga S, Zito MC, Maiuolo J, Macrì R, Amodio N, Juli G, Tassone P, Mollace R, Caffrey R, Marioneaux J, Walker R, Ehrlich J, Palma E, Muscoli C, Bedossa P, Salvemini D, Mollace V, Sanyal AJ.
Sci Rep. 2020 Feb 13;10(1):2565. doi: 10.1038/s41598-020-59485-3.

View Publication
February, 2020

Advances in non-invasive assessment of hepatic fibrosis.

Loomba R, Adams LA.
Gut. 2020 Feb 17. pii: gutjnl-2018-317593. doi: 10.1136/gutjnl-2018-317593.

View Publication
February, 2020

NAFLD 2020: The State of the Disease.

Cotter TG, Rinella M.
Gastroenterology. 2020 Feb 12. pii: S0016-5085(20)30223-7. doi: 10.1053/j.gastro.2020.01.052.

View Publication
February, 2020

An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis.

Zhao P, Sun X, Chaggan C, Liao Z, In Wong K, He F, Singh S, Loomba R, Karin M, Witztum JL, Saltiel AR.
Science. 2020 Feb 7;367(6478):652-660. doi: 10.1126/science.aay0542.

View Publication
February, 2020

Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of Nonalcoholic Fatty Liver Disease.

Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM.
Hepatology. 2020 Feb 11. doi: 10.1002/hep.31173.

View Publication
February, 2020

MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease.

Eslam M, Sanyal AJ, George J; an international consensus panel.
Gastroenterology. 2020 Feb 7. pii: S0016-5085(20)30171-2. doi: 10.1053/j.gastro.2019.11.312.

View Publication
February, 2020

Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis.

Taylor RS, Taylor RJ, Bayliss S, Hagstrom H, Nasr P, Schattenberg JM, Ishigami M, Toyoda H, Wai-Sun Wong V, Peleg N, Shlomai A, Sebastiani G, Seko Y, Bhala N, Younossi ZM, Anstee QM, McPherson S, Newsome PN; Collaborators.
Gastroenterology. 2020 Feb 3. pii: S0016-5085(20)30137-2. doi: 10.1053/j.gastro.2020.01.043.

View Publication
February, 2020

Assessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease by Using Quantitative US.

Han A, Zhang YN, Boehringer AS, Montes V, Andre MP, Erdman JW Jr, Loomba R, Valasek MA, Sirlin CB, O'Brien WD Jr.
Radiology. 2020 Feb 4:191152. doi: 10.1148/radiol.2020191152.

View Publication
February, 2020

Investigating fibrosis and inflammation in an ex vivo NASH murine model.

Gore E, Bigaeva E, Oldenburger A, Jansen YJM, Schuppan D, Boersema M, Rippmann JF, Broermann A, Olinga P.
Am J Physiol Gastrointest Liver Physiol. 2020 Feb 1;318(2):G336-G351. doi: 10.1152/ajpgi.00209.2019.

View Publication
February, 2020

Non-Alcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?

Budd J, Cusi K.
Am J Med. 2020 Feb 1. pii: S0002-9343(20)30100-5. doi: 10.1016/j.amjmed.2020.01.007.

View Publication
February, 2020

The role of nutrition in non-alcoholic fatty liver disease: Pathophysiology and management.

Berná G, Romero-Gomez M.
Liver Int. 2020 Feb;40 Suppl 1:102-108. doi: 10.1111/liv.14360. Review.

View Publication
February, 2020

Current management of non-alcoholic steatohepatitis.

Muthiah MD, Sanyal AJ.
Liver Int. 2020 Feb;40 Suppl 1:89-95. doi: 10.1111/liv.14355.

View Publication
February, 2020

New drugs for non-alcoholic steatohepatitis.

Cardoso AC, de Figueiredo-Mendes C, A Villela-Nogueira C, Sanyal AJ.

Liver Int. 2020 Feb;40 Suppl 1:96-101. doi: 10.1111/liv.14354.

View Publication
February, 2020

Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes.

Cusi K.
Diabetes Care. 2020 Feb;43(2):275-279. doi: 10.2337/dci19-0064.

View Publication
February, 2020

Role of Exercise in Mitigating Pediatric Nonalcoholic Fatty Liver Disease.

Vittorio JM, Lavine JE.
Diabetes Care. 2020 Feb;43(2):280-282. doi: 10.2337/dci19-0029.

View Publication
February, 2020

A diabetologist’s perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions.

Cusi K.
Liver Int. 2020 Feb;40 Suppl 1:82-88. doi: 10.1111/liv.14350.

View Publication
February, 2020

β-arrestin: Dr Jekyll and Mr Hyde in NASH and fibrosis.

Abe H, Schuppan D.
J Hepatol. 2020 May;72(5):813-815. doi: 10.1016/j.jhep.2020.01.016. Epub 2020 Feb 28.

View Publication
January, 2020

Fatty liver disease: putting the spotlight on a silent menace for young adults.

Bugianesi E.
Lancet Gastroenterol Hepatol. 2020 Mar;5(3):236-238. doi: 10.1016/S2468-1253(19)30420-0. Epub 2020 Jan 15. No abstract available.
PMID: 31954686

View Publication
January, 2020

Multicenter validation of association between decline in MRI-PDFF and histologic response in nonalcoholic steatohepatitis.

Loomba R, Neuschwander-Tetri BA, Sanyal A, Chalasani N, Diehl AM, Terrault N, Kowdley K, Dasarathy S, Kleiner D, Behling C, Lavine J, Van Natta M, Middleton M, Tonascia J, Sirlin C; NASH Clinical Research Network.
Hepatology. 2020 Jan 21. doi: 10.1002/hep.31121.

View Publication
January, 2020

AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: Expert Review.

Loomba R, Lim JK, Patton H, El-Serag HB.
Gastroenterology. 2020 Jan 29. pii: S0016-5085(20)30127-X. doi: 10.1053/j.gastro.2019.12.053.

View Publication
January, 2020

Collagen biology and non-invasive biomarkers of liver fibrosis.

Karsdal MA, Daniels SJ, Holm Nielsen S, Bager C, Rasmussen DGK, Loomba R, Surabattula R, Villesen IF, Luo Y, Shevell D, Gudmann NS, Nielsen MJ, George J, Christian R, Leeming DJ, Schuppan D.
Liver Int. 2020 Jan 29. doi: 10.1111/liv.14390.

View Publication
January, 2020

Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.

Ratziu V, Sanyal A, Harrison SA, Wong VW, Francque S, Goodman Z, Aithal GP, Kowdley KV, Seyedkazemi S, Fischer L, Loomba R, Abdelmalek MF, Tacke F.
Hepatology. 2020 Jan 13. doi: 10.1002/hep.31108.

View Publication
December, 2019

Low Awareness of Nonalcoholic Fatty Liver Disease in a Population-Based Cohort Sample: the CARDIA Study.

Cleveland ER, Ning H, Vos MB, Lewis CE, Rinella ME, Carr JJ, Lloyd-Jones DM, VanWagner LB.
J Gen Intern Med. 2019 Dec;34(12):2772-2778. doi: 10.1007/s11606-019-05340-9.

View Publication
December, 2019

Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease.

Vos MB, Dimick-Santos L, Mehta R, Omokaro SO, Taminiau J, Schabel E, Kleiner DE, Szitanyi P, Socha P, Schwimmer JB, Noviello S, Silberg DG, Torstenson R, Miller V, Lavine JE; Liver Forum Pediatric Working Group.
Gastroenterology. 2019 Dec;157(6):1448-1456.e1. doi: 10.1053/j.gastro.2019.08.048.

View Publication
November, 2019

Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.

Rosso C, Kazankov K, Younes R, Esmaili S, Marietti M, Sacco M, Carli F, Gaggini M, Salomone F, Møller HJ, Abate ML, Vilstrup H, Gastaldelli A, George J, Grønbæk H, Bugianesi E.
J Hepatol. 2019 Nov;71(5):1012-1021. doi: 10.1016/j.jhep.2019.06.031.

View Publication
November, 2019

The impact of modifiable risk factors on the long-term outcomes of non-alcoholic fatty liver disease.

Paik JM, Deshpande R, Golabi P, Younossi I, Henry L, Younossi ZM.
Aliment Pharmacol Ther. 2019 Nov 29. doi: 10.1111/apt.15580.

View Publication
November, 2019

The Role of Noninvasive Tests for Differentiating NASH From NAFL and Diagnosing Advanced Fibrosis Among Patients With NAFLD.

Balakrishnan M, Loomba R.
J Clin Gastroenterol. 2019 Nov 26. doi: 10.1097/MCG.0000000000001284.

View Publication
November, 2019

Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.

Poynard T, Peta V, Deckmyn O, Pais R, Ngo Y, Charlotte F, Ngo A, Munteanu M, Imbert-Bismut F, Monneret D, Housset C, Thabut D, Valla D, Boitard C, Castera L, Ratziu V; FLIP consortium, the FibroFrance Group, the EPIC-3 program and the QUID-NASH group.
Eur J Gastroenterol Hepatol. 2019 Nov 25. doi: 10.1097/MEG.0000000000001606.

View Publication
November, 2019

Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.

Majdi A, Aoudjehane L, Ratziu V, Islam T, Afonso MB, Conti F, Mestiri T, Lagouge M, Foufelle F, Ballenghien F, Ledent T, Moldes M, Cadoret A, Fouassier L, Delaunay JL, Aït-Slimane T, Courtois G, Fève B, Scatton O, Prip-Buus C, Rodrigues CMP, Housset C, Gautheron J.
J Hepatol. 2019 Nov 21. pii: S0168-8278(19)30678-6. doi: 10.1016/j.jhep.2019.11.008.

View Publication
November, 2019

Dietary wheat amylase trypsin inhibitors promote features of murine non-alcoholic fatty liver disease.

Ashfaq-Khan M, Aslam M, Qureshi MA, Senkowski MS, Yen-Weng S, Strand S, Kim YO, Pickert G, Schattenberg JM, Schuppan D.
Sci Rep. 2019 Nov 25;9(1):17463. doi: 10.1038/s41598-019-53323-x.

View Publication
November, 2019

A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.

Pedrosa M, Seyedkazemi S, Francque S, Sanyal A, Rinella M, Charlton M, Loomba R, Ratziu V, Kochuparampil J, Fischer L, Vaidyanathan S, Anstee QM.
Contemp Clin Trials. 2019 Nov 13;88:105889. doi: 10.1016/j.cct.2019.105889.  

View Publication
November, 2019

Hypothetical treatment of patients with non-alcoholic steatohepatitis: Potential impact on important clinical outcomes.

Younossi ZM, Tampi RP, Nader F, Younossi IM, Cable R, Srishord M, Racila A.
Liver Int. 2019 Nov 9. doi: 10.1111/liv.14292.   

View Publication
November, 2019

Hepatocellular carcinoma and non-alcoholic fatty liver disease.

Golabi P, Rhea L, Henry L, Younossi ZM.
Hepatol Int. 2019 Nov;13(6):688-694. doi: 10.1007/s12072-019-09995-8.

View Publication
November, 2019

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.

Harrison SA, Alkhouri N, Davison BA, Sanyal A, Edwards C, Colca JR, Lee BH, Loomba R, Cusi K, Kolterman O, Cotter G, Dittrich HC.
J Hepatol. 2019 Nov 4. pii: S0168-8278(19)30650-6. doi: 10.1016/j.jhep.2019.10.023.

View Publication
October, 2019

Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.

Bril F, McPhaul MJ, Caulfield MP, Clark VC, Soldevilla-Pico C, Firpi-Morell RJ, Lai J, Shiffman D, Rowland CM, Cusi K.
Diabetes Care. 2019 Oct 11. pii: dc191071. doi: 10.2337/dc19-1071

View Publication
October, 2019

Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.

Bril F, Barb D, Lomonaco R, Lai J, Cusi K.
J Hepatol. 2019 Oct 4. pii: S0168-8278(19)30584-7. doi: 10.1016/j.jhep.2019.09.018

View Publication
September, 2019

Toward More Accurate Nomenclature for Fatty Liver Diseases

Eslam M, Sanyal AJ, George J.
Gastroenterology. 2019 Sep;157(3):590-593. doi: 10.1053/j.gastro.2019.05.064.

View Publication
September, 2019

Editorial: It is not a wide-open field for incretins – collateral benefits favour the use of metformin in advanced non-alcoholic steatohepatitis

Ratziu V, Pais R.
Aliment Pharmacol Ther. 2019 Sep;50(5):611-612. doi: 10.1111/apt.15414.

View Publication
August, 2019

Gene Expression and DNA Methylation Alterations in the Glycine N-Methyltransferase Gene in Diet-Induced Nonalcoholic Fatty Liver Disease-Associated Carcinogenesis

Borowa-Mazgaj B, de Conti A, Tryndyak V, Steward CR, Jimenez L, Melnyk S, Seneshaw M, Mirshahi F, Rusyn I, Beland FA, Sanyal AJ, Pogribny IP.
Toxicol Sci. 2019 Aug 1;170(2):273-282. doi: 10.1093/toxsci/kfz110.

View Publication
August, 2019

Non-alcoholic fatty liver disease in Asia: How is it different from the West?

Wong GL, Wong VW.
J Gastroenterol Hepatol. 2019 Aug;34(8):1267-1268. doi: 10.1111/jgh.14813.

View Publication
August, 2019

Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial

Bril F, Biernacki DM, Kalavalapalli S, Lomonaco R, Subbarayan SK, Lai J, Tio F, Suman A, Orsak BK, Hecht J, Cusi K.
Diabetes Care. 2019 Aug;42(8):1481-1488. doi: 10.2337/dc19-0167.

View Publication
August, 2019

Degradation of splicing factor SRSF3 contributes to progressive liver disease

Kumar D, Das M, Sauceda C, Ellies LG, Kuo K, Parwal P, Kaur M, Jih L, Bandyopadhyay GK, Burton D, Loomba R, Osborn O, Webster NJ.
J Clin Invest. 2019 Aug 8;130. pii: 127374. doi: 10.1172/JCI127374.

View Publication
July, 2019

FTY720/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in diet-induced nonalcoholic fatty liver disease in mice

Rohrbach TD, Asgharpour A, Maczis MA, Montefusco D, Cowart LA, Bedossa P, Sanyal AJ, Spiegel S.
J Lipid Res. 2019 Jul;60(7):1311-1322. doi: 10.1194/jlr.M093799.

View Publication
July, 2019

Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease

Nobili V, Mantovani A, Cianfarani S, Alisi A, Mosca A, Sartorelli MR, Maffeis C, Loomba R, Byrne CD, Targher G.
J Hepatol. 2019 Jul 4. pii: S0168-8278(19)30395-2. doi: 10.1016/j.jhep.2019.06.023.

View Publication
July, 2019

Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials

Anstee QM, Lawitz EJ, Alkhouri N, Wong VW, Romero-Gomez M, Okanoue T, Trauner M, Kersey K, Li G, Han L, Jia C, Wang L, Chen G, Subramanian GM, Myers RP, Djedjos CS, Kohli A, Bzowej N, Younes Z, Sarin S, Shiffman ML, Harrison SA, Afdhal NH, Goodman Z, Younossi ZM.
Hepatology. 2019 Jul 4. doi: 10.1002/hep.30842.

View Publication
July, 2019

Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity

Newsome P, Francque S, Harrison S, Ratziu V, Van Gaal L, Calanna S, Hansen M, Linder M, Sanyal A.
Aliment Pharmacol Ther. 2019 Jul;50(2):193-203. doi: 10.1111/apt.15316

View Publication
July, 2019

Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications

Jayakumar S, Loomba R.
Aliment Pharmacol Ther. 2019 Jul;50(2):144-158. doi: 10.1111/apt.15314.

View Publication
July, 2019

A new bile acid treatment for non-alcoholic fatty liver disease

Chan WK, Wong VW.
Lancet Gastroenterol Hepatol. 2019 Jul 22. pii: S2468-1253(19)30183-9. doi: 10.1016/S2468-1253(19)30183-9.

View Publication
July, 2019

Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes

Bril F, Leeming DJ, Karsdal MA, Kalavalapalli S, Barb D, Lai J, Rabe M, Cusi K.
Diabetes Care. 2019 Jul;42(7):1348-1351. doi: 10.2337/dc18-2578.

View Publication
July, 2019

Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease

Khoo S, Wong VW, Goh GB, Fan J, Chan WK, Seto WK, Chow WC.
J Gastroenterol Hepatol. 2019 Jul 23. doi: 10.1111/jgh.14794.

View Publication
July, 2019

Neurocognitive Deficits in a Cohort With Class 2 and Class 3 Obesity: Contributions of Type 2 Diabetes and Other Comorbidities

Fernando HJ, Cohen RA, Gullett JM, Friedman J, Ayzengart A, Porges E, Woods AJ, Gunstad J, Ochoa CM, Cusi K, Gonzalez-Louis R, Donahoo WT.
Obesity (Silver Spring). 2019 Jul;27(7):1099-1106. doi: 10.1002/oby.22508.

View Publication
June, 2019

REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis

Ratziu V, Sanyal AJ, Loomba R, Rinella M, Harrison S, Anstee QM, Goodman Z, Bedossa P, MacConell L, Shringarpure R, Shah A, Younossi Z.
Contemp Clin Trials. 2019 Jun 29;84:105803. doi: 10.1016/j.cct.2019.06.017.

View Publication
June, 2019

Insights into the evolving role of the gut microbiome in nonalcoholic fatty liver disease: rationale and prospects for therapeutic intervention

Mouzaki M, Loomba R.
Therap Adv Gastroenterol. 2019 Jun 23;12:1756284819858470. doi: 10.1177/1756284819858470. eCollection 2019.  

View Publication
June, 2019

Development and Validation of Hepamet Fibrosis Scoring System A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis

Ampuero J, Pais R, Aller R, Gallego-Durán R, Crespo J, García-Monzón C, Boursier J, Vilar E, Petta S, Ming-Hua Z, Escudero D, Calleja JL, Aspichueta P, Diago M, Rosales JM, Caballería J, Gómez-Camarero J, Lo Iacono O, Benlloch S, Albillos A, Turnes J, Banales JM, Ratziu V, Romero-Gómez M; HEPAmet Registry.
Clin Gastroenterol Hepatol. 2019 Jun 11. pii: S1542-3565(19)30602-0. doi: 10.1016/j.cgh.2019.05.051.

View Publication
June, 2019

Past, present and future perspectives in nonalcoholic fatty liver disease.

Sanyal AJ.
Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):377-386. doi: 10.1038/s41575-019-0144-8.

View Publication
June, 2019

Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes.

Cusi K.
Hepatology. 2019 Jun;69(6):2318-2322. doi: 10.1002/hep.30670.

View Publication
June, 2019

Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis.

Kalavalapalli S, Bril F, Guingab J, Vergara A, Garrett TJ, Sunny NE, Cusi K.
J Endocrinol. 2019 Jun 1;241(3):293-305. doi: 10.1530/JOE-19-0007.

View Publication
June, 2019

Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma.

Liang LY, Wong VW, Tse YK, Yip TC, Lui GC, Chan HL, Wong GL.
Aliment Pharmacol Ther. 2019 Jun;49(12):1509-1517. doi: 10.1111/apt.15269.

View Publication
May, 2019

Are Non-alcoholic Fatty Liver Disease and Alcoholic Fatty Liver Disease More Than Just Semantics?

Eslam M, Sanyal AJ, George J.
Gastroenterology. 2019 May 31. pii: S0016-5085(19)40982-7. doi: 10.1053/j.gastro.2019.05.064

View Publication
May, 2019

Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis.

Farrell G, Schattenberg JM, Leclercq I, Yeh MM, Goldin R, Teoh N, Schuppan D.
Hepatology. 2019 May;69(5):2241-2257. doi: 10.1002/hep.30333.

View Publication
May, 2019

Hepatic R2* is more strongly associated with proton density fat fraction than histologic liver iron scores in patients with nonalcoholic fatty liver disease.

Bashir M, Wolfson T4, Gamst AC, Fowler KJ, Ohliger M, Shah SN, Alazraki A, Trout AT, Behling C, Allende DS, Loomba R, Sanyal A, Schwimmer J, Lavine JE, Shen W, Tonascia J, Van Natta ML, Mamidipalli A, Hooker J, Kowdley KV, Middleton MS, Sirlin CB; NASH Clinical Research Network (NASH CRN).
J Magn Reson Imaging. 2019 May;49(5):1456-1466. doi: 10.1002/jmri.26312.

View Publication
April, 2019

Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations from the Liver Forum.

Cheung A, Neuschwander-Tetri BA, Kleiner DE, Schabel E, Rinella M, Harrison S, Ratziu V, Sanyal AJ, Loomba R, Jeannin Megnien S, Torstenson R, Miller V; Liver Forum Case Definitions Working Group.
Hepatology. 2019 Apr 29. doi: 10.1002/hep.30672.

View Publication
April, 2019

Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

Lemoine M, Assoumou L, De Wit S, Girard PM, Valantin MA, Katlama C, Necsoi C, Campa P, Huefner AD, Schulze Zur Wiesch J, Rougier H, Bastard JP, Stocker H, Mauss S, Serfaty L, Ratziu V, Menu Y, Schlue J, Behrens G, Bedossa P, Capeau J, Ingiliz P, Costagliola D; ANRS-ECHAM Group.
J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):e86-e94. doi: 10.1097/QAI.0000000000001936.

View Publication
April, 2019

Metabolic characterization of two different non-alcoholic fatty liver disease pre-clinical mouse models.

Gallego-Durán R, Álvarez-Amor L, Gil-Gómez A, Rojas Á, Muñoz-Hernández R, Cádernas-García A, Maya-Miles D, Montero-Vallejo R, Gato S, Sánchez Torrijos Y, Ampuero J, Martín F, Romero-Gómez M.
Rev Esp Enferm Dig. 2019 Apr;111(4):301-307. doi: 10.17235/reed.2019.6083/2018.

View Publication
April, 2019

Analysis of the burden and variability in the management of NAFLD patients in the clinical practice: unifying the required criteria.

Sánchez-Torrijos Y, Ampuero J, Pérez Palacios D, Gallego-Durán R, Romero-Gómez M.
Rev Esp Enferm Dig. 2019 Apr;111(4):270-274. doi: 10.17235/reed.2019.6088/2018.

View Publication
April, 2019

Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD).

Fernández Rodríguez CM, Aller R, Gutiérrez García ML, Ampuero J, Gómez-Camarero J, Martín-Mateos RMª, Burgos-Santamaría D, Rosales JM, Aspichueta P, Buque X, Latorre M, Andrade RJ, Hernández-Guerra M, Romero-Gómez M.
Rev Esp Enferm Dig. 2019 Apr;111(4):264-269. doi: 10.17235/reed.2019.5965/2018.

View Publication
March, 2019

Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis.

Regev A, Palmer M, Avigan MI, Dimick-Santos L, Treem WR, Marcinak JF, Seekins D, Krishna G, Anania FA, Freston JW, Lewis JH, Sanyal AJ, Chalasani N.
Aliment Pharmacol Ther. 2019 Mar;49(6):702-713. doi: 10.1111/apt.15153.

View Publication
March, 2019

Plasma Fibroblast Growth Factor 21 is Associated with Severity of Nonalcoholic Steatohepatitis in Patients with Obesity and Type 2 Diabetes.

Barb D, Bril F, Kalavalapalli S, Cusi K.
J Clin Endocrinol Metab. 2019 Mar 8. pii: jc.2018-02414. doi: 10.1210/jc.2018-02414.

View Publication
March, 2019

The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis.

Poynard T, Peta V, Munteanu M, Charlotte F, Ngo Y, Ngo A, Perazzo H, Deckmyn O, Pais R, Mathurin P, Myers R, Loomba R, Ratziu V; FLIP consortium, the FibroFrance-CPAM group, the FibroFrance-Obese group, and the Selonsertib group.
Eur J Gastroenterol Hepatol. 2019 Mar;31(3):393-402. doi: 10.1097/MEG.0000000000001304.

View Publication
March, 2019

The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Kazankov K, Jørgensen SMD, Thomsen KL, Møller HJ, Vilstrup H, George J, Schuppan D, Grønbæk H.
Nat Rev Gastroenterol Hepatol. 2019 Mar;16(3):145-159. doi: 10.1038/s41575-018-0082-x.

View Publication
February, 2019

Reduced Patient-Reported Outcome Scores Associate with Level of Fibrosis in Patients with Nonalcoholic Steatohepatitis.

Younossi ZM, Stepanova M, Anstee QM, Lawitz EJ, Wai-Sun Wong V, Romero-Gomez M, Kersey K, Li G, Subramanian GM, Myers RP, Djedjos CS, Okanoue T, Trauner M, Goodman Z, Harrison SA.
Clin Gastroenterol Hepatol. 2019 Feb 16. pii: S1542-3565(19)30187-9. doi: 10.1016/j.cgh.2019.02.024.

View Publication
January, 2019

Non-Invasive Assessment of Liver Disease in Patients with NAFLD.

Castera L, Friedrich-Rust M, Loomba R.
Gastroenterology. 2019 Jan 17. pii: S0016-5085(19)30051-4. doi: 10.1053/j.gastro.2018.12.036.

View Publication
January, 2019

Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis.

Ratziu V, Ghabril M, Romero-Gomez M, Svegliati-Baroni G.
Transplantation. 2019 Jan;103(1):28-38. doi: 10.1097/TP.0000000000002483.

View Publication
January, 2019

Diagnostic Accuracy of Non-Invasive Fibrosis Models to Detect Change in Fibrosis Stage.

Siddiqui MS, Yamada G, Vuppalanchi R, Van Natta M, Loomba R, Guy C, Brandman D, Tonanscia J, Chalasani N, Neuschander-Tetri B, Sanyal AJ; NASH Clinical Research Network.
Clin Gastroenterol Hepatol. 2019 Jan 4. pii: S1542-3565(19)30004-7. doi: 10.1016/j.cgh.2018.12.031.

View Publication
December, 2018

Haptoglobin 2 Allele is Associated With Histologic Response to Vitamin E in Subjects With Nonalcoholic Steatohepatitis.

Banini B, Cazanave SC, Yates KP, Asgharpour A, Vincent R, Mirshahi F, Le P, Contos MJ, Tonascia J, Chalasani NP, Kowdley KV, McCullough AJ, Behling CA, Schwimmer JB, Lavine JE, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN).
J Clin Gastroenterol. 2018 Dec 21. doi: 10.1097/MCG.0000000000001142.

View Publication